

Fatality in mice due to oversaturation of cellular microR

Nature

441, 537-541

DOI: [10.1038/nature04791](https://doi.org/10.1038/nature04791)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. <i>Genome Biology</i> , 2006, 7, 231.	3.8	50
2	Gene therapy for viral hepatitis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 1263-1278.	1.4	5
3	Amyotrophic lateral sclerosis and gene therapy. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 462-463.	2.7	3
4	Host-virus interaction: a new role for microRNAs. <i>Retrovirology</i> , 2006, 3, 68.	0.9	209
5	RNA interference as a therapeutic strategy for treating CNS disorders. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 451-456.	0.5	1
6	Knocking down Disease with siRNAs. <i>Cell</i> , 2006, 126, 231-235.	13.5	186

7

#	ARTICLE	IF	CITATIONS
19	Silencing of HIV-1 with RNA Interference: a Multiple shRNA Approach. <i>Molecular Therapy</i> , 2006, 14, 883-892.	3.7	290
20	MicroRNA and 3T3-L1 pre-adipocyte differentiation. <i>Rna</i> , 2006, 12, 1626-1632.	1.6	204
21	The canonical Wnt signalling pathway and its APC partner in colon cancer development. <i>Gut</i> , 2007, 56, 417-425.	6.1	244
22	Nucleic acid drugs in the clinic. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 321-333.	2.5	4
23	Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5715-5721.	3.3	384
24	Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17204-17209.	3.3	378
25	Increasing the robustness and validity of RNAi screens. <i>Pharmacogenomics</i> , 2007, 8, 1037-1049.	0.6	28
26	Strand-specific 5' O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. <i>Rna</i> , 2008, 14, 263-274.	1.6	174
27	Enjoy the Silence: The Story of let-7 MicroRNA and Cancer. <i>Current Genomics</i> , 2007, 8, 229-233.	0.7	78
28	Molecular therapy in the microRNA era. <i>Pharmacogenomics Journal</i> , 2007, 7, 297-304.	0.9	69
29	Critical Role for Fas-Associated Death Domain-Like Interleukin-1-Converting Enzyme-Like Inhibitory Protein in Anoikis Resistance and Distant Tumor Formation. <i>Journal of the National Cancer Institute</i> , 2007, 99, 811-822.	3.0	72
30	Defining the optimal parameters for hairpin-based knockdown constructs. <i>Rna</i> , 2007, 13, 1765-1774.	1.6	84
31	miRNAs. <i>Organogenesis</i> , 2007, 3, 25-33.	0.4	4
32	Specific Inhibition of HBV Replication In Vitro and In Vivo With Expressed Long Hairpin RNA. <i>Molecular Therapy</i> , 2007, 15, 534-541.	3.7	80
33	Rapid and Stable Knockdown of an Endogenous Gene in Retinal Pigment Epithelium. <i>Human Gene Therapy</i> , 2007, 18, 871-880.	1.4	22
34	shRNAs Targeting Hepatitis C: Effects of Sequence and Structural Features, and Comparison with siRNA. <i>Oligonucleotides</i> , 2007, 17, 223-236.	2.7	53
35	Inhibition of Hepatitis C Virus Infection in Cell Culture by Small Interfering RNAs. <i>Molecular Therapy</i> , 2007, 15, 1452-1462.	3.7	41
36	RNA interference based gene therapy for neurological disease. <i>Briefings in Functional Genomics & Proteomics</i> , 2007, 6, 40-49.	3.8	18

#	ARTICLE	IF	CITATIONS
37	MicroRNA and Brain Tumors: A Cause and a Cure?. <i>DNA and Cell Biology</i> , 2007, 26, 301-310.	0.9	31
38	The Inhibitory Efficacy of RNA POL III-Expressed Long Hairpin RNAs Targeted to Untranslated Regions of the HIV-1 5' Long Terminal Repeat. <i>Oligonucleotides</i> , 2007, 17, 419-432.	2.7	38
39	Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. <i>Nucleic Acids Research</i> , 2007, 35, 6598-6610.	6.5	83
40	Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. <i>Rna</i> , 2007, 13, 431-456.	1.6	193
41	Depletion of newly synthesized Argonaute1 impairs the RNAi response in <i>Trypanosoma brucei</i> . <i>Rna</i> , 2007, 13, 1132-1139.	1.6	15
42	Design of extended short hairpin RNAs for HIV-1 inhibition. <i>Nucleic Acids Research</i> , 2007, 35, 5683-5693.	6.5	89
43	Overexpression of Dicer in Precursor Lesions of Lung Adenocarcinoma. <i>Cancer Research</i> , 2007, 67, 2345-2350.	0.4	230
44	Technology Insight: therapeutic RNA interference—how far from the neurology clinic?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 394-404.	2.7	37
45	Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b. <i>Journal of Biological Chemistry</i> , 2007, 282, 1479-1486.	1.6	551
46	siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. <i>Nucleic Acids Research</i> , 2007, 36, e2-e2.	6.5	53
47	Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. <i>Nucleic Acids Research</i> , 2007, 35, 5154-5164.	6.5	249
48	Design and Evaluation of Small Interfering RNAs That Target Expression of the N-Methyl-d-aspartate Receptor NR1 Subunit Gene in the Spinal Cord Dorsal Horn. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 982-988.	1.3	36
49	Optimization and characterization of tRNA-shRNA expression constructs. <i>Nucleic Acids Research</i> , 2007, 35, 2620-2628.	6.5	46
50	microRNAs in Adult Rodent Liver Are Refractory to Dioxin Treatment. <i>Toxicological Sciences</i> , 2007, 99, 470-487.	1.4	78
51	A Preliminary Study towards Downregulation of Murine Bone Marrow Eosinophilopoiesis Mediated by Small Molecule Inhibition of Interleukin-5 Receptor α Gene in vitro. <i>Respiration</i> , 2007, 74, 320-328.	1.2	7
52	Epigenetics and MicroRNAs. <i>Pediatric Research</i> , 2007, 61, 17R-23R.	1.1	94
53	Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13110-13115.	3.3	146
54	Transgenic RNAi Depletion of Claudin-16 and the Renal Handling of Magnesium. <i>Journal of Biological Chemistry</i> , 2007, 282, 17114-17122.	1.6	138

#	ARTICLE	IF	CITATIONS
55	Therapeutic potential of RNA interference in neurodegenerative diseases. <i>Future Neurology</i> , 2007, 2, 237-240.	0.9	0
57	Off-target effects associated with long dsRNAs in <i>Drosophila</i> RNAi screens. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 149-151.	4.0	51
58	RNA Interference: A Tool for Querying Nervous System Function and an Emerging Therapy. <i>Neuron</i> , 2007, 53, 781-788.	3.8	48
59	Lentiviral vector-mediated RNAi and its use for cancer research. <i>Future Oncology</i> , 2007, 3, 655-664.	1.1	30
60	The role of microRNAs in cancer: No small matter. <i>European Journal of Cancer</i> , 2007, 43, 1529-1544.	1.3	318
61	In vivo suppression of <i>mafA</i> mRNA with siRNA and analysis of the resulting alteration of the gene expression profile in mouse pancreas by the microarray method. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 129-135.	1.0	9
62	Parent-of-origin dependent gene-specific knock down in mouse embryos. <i>Biochemical and Biophysical Research Communications</i> , 2007, 358, 727-732.	1.0	13
63	Optimization of short hairpin RNA for lentiviral-mediated RNAi against WAS. <i>Biochemical and Biophysical Research Communications</i> , 2007, 362, 498-503.	1.0	7
64	Potential role of RNAi in the treatment of HCV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 823-831.	2.0	8
65	MicroRNAs in Disease and Potential Therapeutic Applications. <i>Molecular Therapy</i> , 2007, 15, 2070-2079.	3.7	346
66	Dynamic PolyConjugates for targeted <i>in vivo</i> delivery of siRNA to hepatocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12982-12987.	3.3	624
67	Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets?. <i>Molecular Therapy</i> , 2007, 15, 878-888.	3.7	131
68	Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome. <i>BioDrugs</i> , 2007, 21, 9-15.	2.2	15
69	RNAi Therapy for HIV Infection. <i>BioDrugs</i> , 2007, 21, 17-22.	2.2	26
70	miRNA genetic alterations in human cancers. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1375-1386.	1.4	50
71	Targeting neurological disease with RNAi. <i>Molecular BioSystems</i> , 2007, 3, 773.	2.9	15
72	Effective Anti-Hepatitis B Virus Hammerhead Ribozymes Derived from Multimeric Precursors. <i>Oligonucleotides</i> , 2007, 17, 104-112.	2.7	13
73	Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 373-382.	1.1	36

#	ARTICLE	IF	CITATIONS
74	RNAi and Gene Therapy: A Mutual Attraction. Hematology American Society of Hematology Education Program, 2007, 2007, 473-481.	0.9	75
75	High-Capacity Adenoviral Vector-Mediated Reduction of Huntingtin Aggregate Load In Vitro and In Vivo. Human Gene Therapy, 2007, 18, 303-311.	1.4	52
76	The Power of Silence: Application of Small Interfering RNAs to Gastrointestinal Diseases. Gastroenterology, 2007, 132, 2291-2295.	0.6	4
77	Applications of RNA Interference in Mammalian Systems. Annual Review of Genomics and Human Genetics, 2007, 8, 81-108.	2.5	124
78	MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?. Expert Opinion on Therapeutic Targets, 2007, 11, 181-189.	1.5	54
79	A Review of Recent Patents Concerning Therapy of Respiratory Diseases Using Gene Silencing by RNAi (RISC) and EGS (RNase P). Recent Patents on Inflammation and Allergy Drug Discovery, 2007, 1, 49-55.	3.9	2
80	Silencing of the <i>Pink1</i> Gene Expression by Conditional RNAi Does Not Induce Dopaminergic Neuron Death in Mice. International Journal of Biological Sciences, 2007, 3, 242-250.	2.6	80
81	Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2007, 6, 19-27.	1.1	0
82	MicroRNA epigenetic alterations in human cancer: One step forward in diagnosis and treatment. International Journal of Cancer, 2008, 122, 963-968.	2.3	84
83	RNAi for revealing and engineering plant gene functions. Current Opinion in Biotechnology, 2007, 18, 148-153.	3.3	128
84	Boundary cap cells constrain spinal motor neuron somal migration at motor exit points by a semaphorin-plexin mechanism. Neural Development, 2007, 2, 21.	1.1	110
85	Antisense—down, but not out. Nature Biotechnology, 2007, 25, 497-499.	9.4	30
86	Australia tackles bird flu using RNAi. Nature Biotechnology, 2007, 25, 605-606.	9.4	4
87	Companies jostle for lead in RNAi, despite uncertainties. Nature Biotechnology, 2007, 25, 1191-1192.	9.4	6
88	Genetic therapies against HIV. Nature Biotechnology, 2007, 25, 1444-1454.	9.4	214
89	RNA interference against viruses: strike and counterstrike. Nature Biotechnology, 2007, 25, 1435-1443.	9.4	266
90	Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nature Biotechnology, 2007, 25, 1457-1467.	9.4	539
91	RNA learns from antisense. , 2007, 3, 8-11.		87

#	ARTICLE	IF	CITATIONS
92	Tissue-specific and reversible RNA interference in transgenic mice. <i>Nature Genetics</i> , 2007, 39, 914-921.	9.4	170
93	Interfering with disease: a progress report on siRNA-based therapeutics. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 443-453.	21.5	1,080
94	Strategies for silencing human disease using RNA interference. <i>Nature Reviews Genetics</i> , 2007, 8, 173-184.	7.7	976
95	Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. <i>Gene Therapy</i> , 2007, 14, 11-19.	2.3	74
96	Progress and prospects: RNA-based therapies for treatment of HIV infection. <i>Gene Therapy</i> , 2007, 14, 1057-1064.	2.3	77
97	Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters. <i>Gene Therapy</i> , 2007, 14, 1503-1512.	2.3	29
98	Fine-tuning of the innate immune response by microRNAs. <i>Immunology and Cell Biology</i> , 2007, 85, 458-462.	1.0	99
99	In vivo post-transcriptional gene silencing of α -1 antitrypsin by adeno-associated virus vectors expressing siRNA. <i>Laboratory Investigation</i> , 2007, 87, 893-902.	1.7	57
100	Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. <i>Nature</i> , 2007, 449, 745-747.	13.7	145
101	Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. <i>Journal of Viral Hepatitis</i> , 2007, 14, 447-459.	1.0	33
102	Regulation and guidance of cell behavior for tissue regeneration via the siRNA mechanism. <i>Wound Repair and Regeneration</i> , 2007, 15, 286-295.	1.5	46
103	Cyclin A2 Regulates Nuclear-Envelope Breakdown and the Nuclear Accumulation of Cyclin B1. <i>Current Biology</i> , 2007, 17, 85-91.	1.8	132
104	In silico selection of active siRNA. <i>Drug Discovery Today</i> , 2007, 12, 139-148.	3.2	49
105	Mining the GEMS – a novel platform technology targeting post-transcriptional control mechanisms. <i>Drug Discovery Today</i> , 2007, 12, 553-560.	3.2	14
106	Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. <i>Vision Research</i> , 2007, 47, 1202-1208.	0.7	61
107	microRNAs: a new emerging class of players for disease diagnostics and gene therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 3-21.	1.6	125
108	Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. , 2007, 114, 34-55.		43
109	RNAi therapeutics: Principles, prospects and challenges. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 75-86.	6.6	780

#	ARTICLE	IF	CITATIONS
110	Therapeutic potential for microRNAs. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 101-114.	6.6	174
111	Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 164-182.	6.6	199
112	Therapeutic application of RNA interference for hepatitis C virus. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1263-1276.	6.6	37
113	Germ line transmission and expression of an RNAi cassette in mice generated by a lentiviral vector system. <i>Transgenic Research</i> , 2007, 16, 783-793.	1.3	8
114	New technology for an old favorite: lentiviral transgenesis and RNAi in rats. <i>Transgenic Research</i> , 2007, 16, 571-580.	1.3	44
115	Prnp knockdown in transgenic mice using RNA interference. <i>Transgenic Research</i> , 2008, 17, 783-791.	1.3	12
116	Tat-regulated expression of RNA interference: Triggers for the treatment of HIV infection. <i>Current HIV/AIDS Reports</i> , 2008, 5, 40-43.	1.1	1
117	Molecular therapy and prevention of liver diseases. <i>Virologica Sinica</i> , 2008, 23, 81-92.	1.2	2
118	Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of dicer expression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 629-635.	1.4	47
119	A construct with fluorescent indicators for conditional expression of miRNA. <i>BMC Biotechnology</i> , 2008, 8, 77.	1.7	37
120	Inhibition of HBV gene expression and replication by stably expressed interferon α 1 via adeno-associated viral vectors. <i>Journal of Gene Medicine</i> , 2008, 10, 619-627.	1.4	5
121	Recent developments in adeno-associated virus vector technology. <i>Journal of Gene Medicine</i> , 2008, 10, 717-733.	1.4	165
122	Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice. <i>Journal of Gene Medicine</i> , 2008, 10, 878-889.	1.4	25
123	Systemic cancer therapy: Evolution over the last 60 years. <i>Cancer</i> , 2008, 113, 1857-1887.	2.0	43
124	A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver. <i>Hepatology</i> , 2008, 47, 1714-1724.	3.6	53
125	Transcriptional gene silencing as a genetic therapy for HIV-1. <i>Future HIV Therapy</i> , 2008, 2, 339-349.	0.5	2
126	Conditional transgenic mouse models: from the basics to genome-wide sets of knockouts and current studies of tissue regeneration. <i>Regenerative Medicine</i> , 2008, 3, 217-235.	0.8	45
127	Delivery Vehicles for Small Interfering RNA In Vivo. <i>Human Gene Therapy</i> , 2008, 19, 125-132.	1.4	215

#	ARTICLE	IF	CITATIONS
128	RNA interference: An emerging generation of biologicals. <i>Biotechnology Journal</i> , 2008, 3, 339-353.	1.8	42
129	Spermatogonial Stem Cell Self-Renewal Requires OCT4, a Factor Downregulated During Retinoic Acid-Induced Differentiation. <i>Stem Cells</i> , 2008, 26, 2928-2937.	1.4	181
130	Specific expression of short-interfering RNA driven by human telomerase reverse transcriptase promoter in tumor cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2008, 40, 928-933.	0.9	1
131	Treatment with small interfering RNA affects the microRNA pathway and causes unspecific defects in zebrafish embryos. <i>FEBS Journal</i> , 2008, 275, 2177-2184.	2.2	38
132	Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. <i>Gene Therapy</i> , 2008, 15, 1536-1549.	2.3	107
133	AAV vectors for RNA-based modulation of gene expression. <i>Gene Therapy</i> , 2008, 15, 864-869.	2.3	15
134	A skin microRNA promotes differentiation by repressing "stemness". <i>Nature</i> , 2008, 452, 225-229.	13.7	735
135	Knockdown of porcine endogenous retrovirus (PERV) expression by PERV-specific shRNA in transgenic pigs. <i>Xenotransplantation</i> , 2008, 15, 36-45.	1.6	156
136	Review article: RNA interference " potential therapeutic applications for the gastroenterologist. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 715-723.	1.9	9
137	Double-stranded RNA interferes in a sequence-specific manner with the infection of representative members of the two viroid families. <i>Virology</i> , 2008, 371, 44-53.	1.1	106
138	Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. <i>Antiviral Research</i> , 2008, 78, 26-36.	1.9	83
139	<i>Schistosoma mansoni</i> : Evaluation of an RNAi-based treatment targeting HGPRTase gene. <i>Experimental Parasitology</i> , 2008, 118, 619-623.	0.5	40
140	Maintaining the silence: reflections on long-term RNAi. <i>Drug Discovery Today</i> , 2008, 13, 917-931.	3.2	106
141	Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. <i>Neurobiology of Disease</i> , 2008, 29, 446-455.	2.1	21
142	MicroRNAs as targets for antisense-based therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 59-81.	1.4	105
144	Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 2641-2650.	13.9	633
145	Not miR-ly small RNAs: Big potential for microRNAs in therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 309-319.	1.5	63
146	Current Perspectives in microRNAs (miRNA). , 2008, , .		3

#	ARTICLE	IF	CITATIONS
147	Identifying siRNA-Induced Off-Targets by Microarray Analysis. <i>Methods in Molecular Biology</i> , 2008, 442, 45-63.	0.4	28
148	RNAi. <i>Methods in Molecular Biology</i> , 2008, 442, vii-viii.	0.4	0
149	Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice. <i>Molecular and Cellular Neurosciences</i> , 2008, 37, 579-589.	1.0	68
150	miR-122, a paradigm for the role of microRNAs in the liver. <i>Journal of Hepatology</i> , 2008, 48, 648-656.	1.8	330
151	Can phages cause Alzheimer's disease?. <i>Medical Hypotheses</i> , 2008, 71, 651-656.	0.8	3
152	RNA Interference in Research and Therapy of Renal Diseases. , 2008, 159, 78-95.		11
153	Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 637-645.	1.5	112
154	siRNA-mediated Erc gene silencing suppresses tumor growth in Tsc2 mutant renal carcinoma model. <i>Cancer Letters</i> , 2008, 268, 278-285.	3.2	11
155	Competition potency of siRNA is specified by the 5'-half sequence of the guide strand. <i>Biochemical and Biophysical Research Communications</i> , 2008, 367, 78-83.	1.0	16
156	Adverse effects induced by short hairpin RNA expression in porcine fetal fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2008, 370, 113-117.	1.0	36
157	T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice. <i>Cell</i> , 2008, 134, 577-586.	13.5	542
158	siRNA and the lung: research tool or therapeutic drug?. <i>Current Opinion in Pharmacology</i> , 2008, 8, 280-285.	1.7	45
159	Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. <i>Nucleic Acids Research</i> , 2008, 36, 4158-4171.	6.5	402
160	Targeted mRNA degradation by complex-mediated delivery of antisense RNAs to intracellular human mitochondria. <i>Human Molecular Genetics</i> , 2008, 17, 1292-1298.	1.4	27
161	Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?. <i>Cancer Gene Therapy</i> , 2008, 15, 341-355.	2.2	230
162	Ribonucleases as Novel Chemotherapeutics. <i>BioDrugs</i> , 2008, 22, 53-58.	2.2	96
163	In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses. <i>Journal of Virology</i> , 2008, 82, 5887-5911.	1.5	546
164	The Business of RNAi Therapeutics. <i>Human Gene Therapy</i> , 2008, 19, 451-462.	1.4	66

#	ARTICLE	IF	CITATIONS
165	Advances in MicroRNAs: Implications for Gene Therapists. <i>Human Gene Therapy</i> , 2008, 19, 27-38.	1.4	46
166	Oligonucleotidic therapeutics. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 991-996.	2.5	7
167	Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. <i>Nucleic Acids Research</i> , 2008, 36, 2811-2824.	6.5	193
168	Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9284-9289.	3.3	91
169	siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. <i>Human Molecular Genetics</i> , 2008, 17, 1436-1445.	1.4	63
170	Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. <i>Rna</i> , 2008, 14, 1834-1844.	1.6	130
171	Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10). <i>Human Molecular Genetics</i> , 2008, 17, 2084-2100.	1.4	58
172	Behind the Scenes of a Small RNA Gene-Silencing Pathway. <i>Human Gene Therapy</i> , 2008, 19, 17-26.	1.4	24
173	Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18507-18512.	3.3	149
174	Helper-dependent Adenovirus-mediated Short Hairpin RNA Expression in the Liver Activates the Interferon Response. <i>Journal of Biological Chemistry</i> , 2008, 283, 2120-2128.	1.6	33
175	Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5868-5873.	3.3	540
176	Silencing of Hepatic Fatty Acid Transporter Protein 5 in Vivo Reverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia. <i>Journal of Biological Chemistry</i> , 2008, 283, 22186-22192.	1.6	133
177	RNA interference and its therapeutic potential against HIV infection. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 449-461.	1.4	25
178	Therapeutic Gene Silencing Delivered by a Chemically Modified Small Interfering RNA against Mutant SOD1 Slows Amyotrophic Lateral Sclerosis Progression. <i>Journal of Biological Chemistry</i> , 2008, 283, 15845-15852.	1.6	53
179	Short Hairpin RNA Interference Therapy for Ischemic Heart Disease. <i>Circulation</i> , 2008, 118, S226-33.	1.6	89
180	MicroRNAs-Based Therapeutic Strategy for Virally Induced Diseases. <i>Current Drug Discovery Technologies</i> , 2008, 5, 49-58.	0.6	22
181	Adjuvant Therapy with Small Hairpin RNA Interference Prevents Non-Small Cell Lung Cancer Metastasis Development in Mice. <i>Cancer Research</i> , 2008, 68, 1896-1904.	0.4	32
182	Modeling oncogene addiction using RNA interference. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 12480-12484.	3.3	41

#	ARTICLE	IF	CITATIONS
183	AAV Vector-mediated RNAi of Mutant Huntingtin Expression Is Neuroprotective in a Novel Genetic Rat Model of Huntington's Disease. <i>Molecular Therapy</i> , 2008, 16, 947-956.	3.7	135
185	Role of Repeat-Associated MicroRNA (ramRNA) in Fragile X Syndrome (FXS). , 2008, , 245-266.		2
186	microRNA-Associated Therapies. , 2008, , 395-429.		3
187	siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. <i>Nucleic Acids Research</i> , 2008, 36, 6944-6944.	6.5	16
188	Rescue of Pituitary Function in a Mouse Model of Isolated Growth Hormone Deficiency Type II by RNA Interference. <i>Endocrinology</i> , 2008, 149, 580-586.	1.4	14
189	RNAi as a potential new therapy for HIV infection. <i>Future HIV Therapy</i> , 2008, 2, 567-577.	0.5	1
190	Expression of shRNA From a Tissue-specific pol II Promoter Is an Effective and Safe RNAi Therapeutic. <i>Molecular Therapy</i> , 2008, 16, 1630-1636.	3.7	183
191	Expressed Anti-HBV Primary MicroRNA Shuttles Inhibit Viral Replication Efficiently In Vitro and In Vivo. <i>Molecular Therapy</i> , 2008, 16, 1105-1112.	3.7	86
192	A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 299-313.	1.4	15
193	Gene Therapy to Induce Cellular Resistance to HIV-1 Infection: Lessons from Clinical Trials. <i>Advances in Pharmacology</i> , 2008, 56, 297-325.	1.2	6
194	TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery. <i>Biotechnology and Genetic Engineering Reviews</i> , 2008, 25, 113-128.	2.4	8
195	MicroRNAs and cancer: An overview. <i>Cell Cycle</i> , 2008, 7, 2485-2492.	1.3	325
196	Efficient Inhibition of Hepatitis B Virus Replication In Vivo, Using Polyethylene Glycol-Modified Adenovirus Vectors. <i>Human Gene Therapy</i> , 2008, 19, 1325-1332.	1.4	38
197	Tissue-Specific shRNA Delivery: A Novel Approach for Gene Therapy in Cancer. <i>Connective Tissue Research</i> , 2008, 49, 265-269.	1.1	19
198	Expression Strategies for Short Hairpin RNA Interference Triggers. <i>Human Gene Therapy</i> , 2008, 19, 313-317.	1.4	61
199	Gene-Targeted Therapies for the Central Nervous System. <i>Archives of Neurology</i> , 2008, 65, 447.	4.9	22
200	Modulation of Cellular Invasion by VEGF-C Expression in Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology</i> , 2008, 134, 355.	1.5	17
201	The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. <i>Blood</i> , 2008, 111, 856-864.	0.6	137

#	ARTICLE	IF	CITATIONS
202	MicroRNA: an Emerging Therapeutic Target and Intervention Tool. International Journal of Molecular Sciences, 2008, 9, 978-999.	1.8	158
203	shRNA: solving the subtle. Science-Business EXchange, 2008, 1, 275-275.	0.0	0
204	Applications of Lentiviral Vectors for shRNA Delivery and Transgenesis. Current Gene Therapy, 2008, 8, 483-488.	0.9	91
205	Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases. Recent Patents on DNA & Gene Sequences, 2008, 2, 40-43.	0.7	4
206	Cellular Delivery In Vivo of siRNA-Based Therapeutics. Current Pharmaceutical Design, 2008, 14, 3603-3619.	0.9	79
207	The Design of Vectors for RNAi Delivery System. Current Pharmaceutical Design, 2008, 14, 1327-1340.	0.9	22
208	RNA Interference: New Therapeutics in Allergic Diseases. Current Gene Therapy, 2008, 8, 236-246.	0.9	13
209	Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics In Vitro: Quantitative Evaluation of Overall Efficacy Employing Easy to Handle Reporter Systems. Current Pharmaceutical Design, 2008, 14, 3637-3655.	0.9	46
210	Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders. Current Gene Therapy, 2008, 8, 461-473.	0.9	139
212	RNA as a Therapeutic Molecule. , 2008, , 691-699.		0
213	The Efficacy of Generating Three Independent Anti-HIV-1 siRNAs from a Single U6 RNA Pol III-Expressed Long Hairpin RNA. PLoS ONE, 2008, 3, e2602.	1.1	49
214	DICER1 and PRKRA in Colon Adenocarcinoma. Biomarker Insights, 2008, 3, BMI.S600.	1.0	8
215	Regulation of Gene Expression by Small, Non-Coding RNAs: Practical Applications. , 0, , 327-347.		0
216	Mir-434-5p mediates skin whitening and lightening. Clinical, Cosmetic and Investigational Dermatology, 2008, 1, 19.	0.8	36
217	Inducible Transgenic Rat Model for Diabetes Mellitus Based on shRNA-Mediated Gene Knockdown. PLoS ONE, 2009, 4, e5124.	1.1	37
218	Design of RNAi Hairpins for Mutation-Specific Silencing of Ataxin-7 and Correction of a SCA7 Phenotype. PLoS ONE, 2009, 4, e7232.	1.1	57
219	Protection of Stem Cell-Derived Lymphocytes in a Primate AIDS Gene Therapy Model after In Vivo Selection. PLoS ONE, 2009, 4, e7693.	1.1	60
220	Therapeutic Potential of RNA Interference in Pain Medicine. Open Pain Journal, 2009, 2, 57-63.	0.4	19

#	ARTICLE	IF	CITATIONS
221	Overview of Gene Silencing by RNA Interference. <i>Current Protocols in Nucleic Acid Chemistry</i> , 2009, 36, Unit 16.1.	0.5	13
222	Transkingdom RNA interference (tkRNAi) as a new delivery tool for therapeutic RNA. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1533-1542.	1.4	5
223	Cell Line Development. <i>Cell Engineering</i> , 2009, , .	0.4	1
224	Robust Hepatic Gene Silencing for Functional Studies Using Helper-Dependent Adenoviral Vectors. <i>Human Gene Therapy</i> , 2009, 20, 87-94.	1.4	21
225	Chronic Reduction of the Cytosolic or Mitochondrial NAD(P)-malic Enzyme Does Not Affect Insulin Secretion in a Rat Insulinoma Cell Line. <i>Journal of Biological Chemistry</i> , 2009, 284, 35359-35367.	1.6	26
226	Novel HIV-1 therapeutics through targeting altered host cell pathways. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1369-1382.	1.4	26
227	A novel method for tissue-specific RNAi rescue in <i>Drosophila</i> . <i>Nucleic Acids Research</i> , 2009, 37, e93-e93.	6.5	22
228	Forward and robust selection of the most potent and noncellular toxic siRNAs from RNAi libraries. <i>Nucleic Acids Research</i> , 2009, 37, e8-e8.	6.5	11
229	Vero Cells as a Model to Study the Effects of Adenoviral Gene Delivery Vectors on the RNAi System in Context of Viral Infection. <i>Journal of Innate Immunity</i> , 2009, 1, 389-394.	1.8	20
230	MicroRNAs as a New Potential Therapeutic Opportunity in Gastrointestinal Cancer. <i>Oncology</i> , 2009, 77, 75-89.	0.9	6
231	Rational Design Leads to More Potent RNA Interference Against Hepatitis B Virus: Factors Effecting Silencing Efficiency. <i>Molecular Therapy</i> , 2009, 17, 538-547.	3.7	37
232	Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. <i>Nucleic Acids Research</i> , 2009, 37, e91-e91.	6.5	63
233	RNA Interference-Based Gene Expression Strategies Aimed at Sustained Therapeutic Inhibition of HIV. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1065-1078.	1.0	10
234	Comparative Study of Anti-hepatitis B Virus RNA Interference by Double-stranded Adeno-associated Virus Serotypes 7, 8, and 9. <i>Molecular Therapy</i> , 2009, 17, 352-359.	3.7	61
235	Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 70-80.	1.1	41
236	The Potential of Modulating Small RNA Activity In Vivo. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 235-248.	1.1	14
237	Amelioration of Psoriasis by Anti-TNF- α RNAi in the Xenograft Transplantation Model. <i>Molecular Therapy</i> , 2009, 17, 1743-1753.	3.7	67
238	Strategies for short hairpin RNA delivery in cancer gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1357-1368.	1.4	37

#	ARTICLE	IF	CITATIONS
239	Allele-specific RNAi Mitigates Phenotypic Progression in a Transgenic Model of Alzheimer's Disease. <i>Molecular Therapy</i> , 2009, 17, 1563-1573.	3.7	48
240	MicroRNAs and the Regulation of Vector Tropism. <i>Molecular Therapy</i> , 2009, 17, 409-416.	3.7	90
241	Asymmetric Shorter-duplex siRNA Structures Trigger Efficient Gene Silencing With Reduced Nonspecific Effects. <i>Molecular Therapy</i> , 2009, 17, 725-732.	3.7	104
242	Dose Optimization for Long-term rAAV-mediated RNA Interference in the Nigrostriatal Projection Neurons. <i>Molecular Therapy</i> , 2009, 17, 1574-1584.	3.7	67
243	Nanoparticles for human liver-specific drug and gene delivery systems: <i>in vitro</i> and <i>in vivo</i> advances. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 39-52.	2.4	41
244	Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs <i>In vitro</i> and <i>In vivo</i> . <i>Molecular Therapy</i> , 2009, 17, 169-175.	3.7	324
245	Towards a durable RNAi gene therapy for HIV-AIDS. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 161-170.	1.4	25
246	New insights into HBV replication: new opportunities for improved therapies. <i>Future Virology</i> , 2009, 4, 55-70.	0.9	22
247	Vascular Smooth Muscle-Specific Knockdown of the Noncardiac Form of the L-Type Calcium Channel by MicroRNA-Based Short Hairpin RNA as a Potential Antihypertensive Therapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 775-782.	1.3	22
248	RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs. <i>Nucleic Acids Research</i> , 2009, 37, e127-e127.	6.5	19
249	Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy. <i>Circulation</i> , 2009, 119, 1241-1252.	1.6	200
250	Overcoming obstacles to develop effective and safe siRNA therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 609-619.	1.4	36
251	Therapeutic potential of RNA interference in drug-resistant cancers. <i>Future Oncology</i> , 2009, 5, 169-185.	1.1	24
252	Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. <i>Human Molecular Genetics</i> , 2009, 18, R27-R39.	1.4	70
253	Essential and overlapping functions for mammalian Argonautes in microRNA silencing. <i>Genes and Development</i> , 2009, 23, 304-317.	2.7	208
254	RNA-interference-based Gene Therapy Approaches to HIV Type-1 Treatment: Tackling the Hurdles from Bench to Bedside. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 19, 221-233.	0.3	9
255	siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs. <i>Drug Discovery Today</i> , 2009, 14, 851-858.	3.2	38
256	siRNAs: their potential as therapeutic agents – Part II. Methods of delivery. <i>Drug Discovery Today</i> , 2009, 14, 859-865.	3.2	33

#	ARTICLE	IF	CITATIONS
257	Human H1 promoter expressed short hairpin RNAs (shRNAs) suppress avian influenza virus replication in chicken CH-SAH and canine MDCK cells. <i>Antiviral Research</i> , 2009, 84, 159-167.	1.9	12
258	Silencing efficiency differs among tissues and endogenous microRNA pathway is preserved in short hairpin RNA transgenic mice. <i>FEBS Letters</i> , 2009, 583, 213-218.	1.3	7
259	Non-nematode-derived double-stranded RNAs induce profound phenotypic changes in <i>Meloidogyne incognita</i> and <i>Globodera pallida</i> infective juveniles. <i>International Journal for Parasitology</i> , 2009, 39, 1503-1516.	1.3	46
261	Delivery of Therapeutic RNAi by Nanovehicles. <i>ChemBioChem</i> , 2009, 10, 2449-2454.	1.3	28
262	Toward RNA interference-based therapy for filovirus infections. <i>Drug Development Research</i> , 2009, 70, 246-254.	1.4	2
263	Stable silencing of the glucocorticoid receptor in myelin-specific T effector cells by retroviral delivery of shRNA: Insight into neuroinflammatory disease. <i>European Journal of Immunology</i> , 2009, 39, 2361-2370.	1.6	6
264	RNAi-based therapeutics—current status, challenges and prospects. <i>EMBO Molecular Medicine</i> , 2009, 1, 142-151.	3.3	238
265	Preconditioning, organ preservation, and postconditioning to prevent ischemia-reperfusion injury to the liver. <i>Liver Transplantation</i> , 2009, 15, 1172-1182.	1.3	118
266	Profiling RNA interference (RNAi)-mediated toxicity in neural cultures for effective short interfering RNA design. <i>Journal of Gene Medicine</i> , 2009, 11, 523-534.	1.4	29
267	Stringent testing identifies highly potent and escape-proof anti-HIV short hairpin RNAs. <i>Journal of Gene Medicine</i> , 2009, 11, 459-467.	1.4	30
268	Neuron-specific RNA interference using lentiviral vectors. <i>Journal of Gene Medicine</i> , 2009, 11, 559-569.	1.4	40
269	AAV gene therapy as a means to increase apolipoprotein (Apo) A and high-density lipoprotein-cholesterol levels: correction of murine ApoA deficiency. <i>Journal of Gene Medicine</i> , 2009, 11, 697-707.	1.4	16
270	RNA Interference: From Basic Research to Therapeutic Applications. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 1378-1398.	7.2	288
271	A quick and efficient approach for gene silencing by using triple putative microRNA-based short hairpin RNAs. <i>Molecular and Cellular Biochemistry</i> , 2009, 323, 81-89.	1.4	21
272	Rapid generation of dendritic cell specific transgenic mice by lentiviral vectors. <i>Transgenic Research</i> , 2009, 18, 921-931.	1.3	8
273	The Therapeutic Potential of microRNAs in Nervous System Damage, Degeneration, and Repair. <i>NeuroMolecular Medicine</i> , 2009, 11, 153-161.	1.8	43
274	Notch Promotes Radioresistance of Glioma Stem Cells. <i>Stem Cells</i> , 2010, 28, 17-28.	1.4	505
275	Regulation of MicroRNA Biogenesis: A miRiad of mechanisms. <i>Cell Communication and Signaling</i> , 2009, 7, 18.	2.7	274

#	ARTICLE	IF	CITATIONS
276	Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5. <i>Genetic Vaccines and Therapy</i> , 2009, 7, 8.	1.5	39
277	Progress and Prospects: The design and production of plasmid vectors. <i>Gene Therapy</i> , 2009, 16, 165-171.	2.3	173
278	The promises and pitfalls of RNA-interference-based therapeutics. <i>Nature</i> , 2009, 457, 426-433.	13.7	1,126
279	Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. <i>Nature Biotechnology</i> , 2009, 27, 549-555.	9.4	470
280	Multitarget therapy of malignant cancers by the head-to-tail tandem array multiple shRNAs expression system. <i>Cancer Gene Therapy</i> , 2009, 16, 516-531.	2.2	19
281	Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. <i>Cancer Gene Therapy</i> , 2009, 16, 807-809.	2.2	82
282	Simultaneous knockdown of the expression of two genes using multiple shRNAs and subsequent knock-in of their expression. <i>Nature Protocols</i> , 2009, 4, 1338-1348.	5.5	27
283	Knocking down barriers: advances in siRNA delivery. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 129-138.	21.5	2,639
284	Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 144-150.	3.6	383
285	Toward a Durable Anti-HIV Gene Therapy Based on RNA Interference. <i>Annals of the New York Academy of Sciences</i> , 2009, 1175, 3-14.	1.8	31
286	RNA Interference Inhibitors of Hepatitis B Virus. <i>Annals of the New York Academy of Sciences</i> , 2009, 1175, 15-23.	1.8	21
287	Long-term RNA interference and its application to hepatitis B virus. <i>Journal of Digestive Diseases</i> , 2009, 10, 165-171.	0.7	5
288	Akt1 silencing efficiencies in lung cancer cells by sh/si/ssiRNA transfection using a reductable polyspermine carrier. <i>Biomaterials</i> , 2009, 30, 1635-1647.	5.7	33
289	RNA interference against aldehyde dehydrogenase-2: development of tools for alcohol research. <i>Alcohol</i> , 2009, 43, 97-104.	0.8	12
290	MicroRNAs in Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 199-227.	9.6	1,218
291	Therapeutic MicroRNA Strategies in Human Cancer. <i>AAPS Journal</i> , 2009, 11, 747-57.	2.2	153
292	siRNA Conjugate Delivery Systems. <i>Bioconjugate Chemistry</i> , 2009, 20, 5-14.	1.8	300
293	Engineering Cell Function by RNA Interference. <i>Cell Engineering</i> , 2009, , 175-194.	0.4	0

#	ARTICLE	IF	CITATIONS
294	Lentiviral delivery of short hairpin RNAs. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 732-745.	6.6	137
295	siRNA vs. shRNA: Similarities and differences. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 746-759.	6.6	500
296	Nonviral vector-mediated RNA interference: Its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 760-766.	6.6	97
297	Short interfering RNA-mediated gene silencing; towards successful application in human patients. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 668-671.	6.6	15
298	Small silencing RNAs: State-of-the-art. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 672-703.	6.6	164
299	Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice. <i>Molecular Therapy</i> , 2009, 17, 1053-1063.	3.7	305
300	Controlling HBV Replication <i>in Vivo</i> by Intravenous Administration of Triggered PEGylated siRNA-Nanoparticles. <i>Molecular Pharmaceutics</i> , 2009, 6, 706-717.	2.3	112
301	Regulated and Multiple miRNA and siRNA Delivery Into Primary Cells by a Lentiviral Platform. <i>Molecular Therapy</i> , 2009, 17, 1039-1052.	3.7	83
302	Progress towards Therapeutic Application of RNA Interference for HIV Infection. <i>BioDrugs</i> , 2009, 23, 269-276.	2.2	15
303	Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy. <i>Experimental Eye Research</i> , 2009, 88, 859-879.	1.2	14
304	Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model. <i>Cell</i> , 2009, 137, 1005-1017.	13.5	1,634
305	Stable Argonaute2 overexpression differentially regulates microRNA production. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2009, 1789, 153-159.	0.9	18
306	Potential pharmacological control of the NF- κ B pathway. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 313-321.	4.0	160
307	siRNA delivery using peptide transduction domains. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 341-345.	4.0	106
308	In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. <i>Methods</i> , 2009, 49, 70-77.	1.9	40
309	A non-invasive method for silencing gene transcription in honeybees maintained under natural conditions. <i>Insect Biochemistry and Molecular Biology</i> , 2009, 39, 157-160.	1.2	71
310	Prospects of RNAi and microRNA-based therapies for hepatitis C. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 713-724.	1.4	20
311	RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 535-538.	1.4	32

#	ARTICLE	IF	CITATIONS
312	Approaches to target the genome and its epigenome in cancer. <i>Future Medicinal Chemistry</i> , 2009, 1, 1481-1495.	1.1	10
313	RNA interference as an anticancer therapy: a patent perspective. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 475-491.	2.4	24
314	High mobility group A: A novel biomarker and therapeutic target in pancreatic adenocarcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2009, 7, 297-306.	0.8	11
315	MicroRNAs: Key Modulators of Posttranscriptional Gene Expression. <i>Gastroenterology</i> , 2009, 136, 17-25.	0.6	95
316	Disruption of Dicer1 Induces Dysregulated Fetal Gene Expression and Promotes Hepatocarcinogenesis. <i>Gastroenterology</i> , 2009, 136, 2304-2315.e4.	0.6	167
317	RNA Inhibition, MicroRNAs, and New Therapeutic Agents for Cancer Treatment. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S313-S318.	1.4	30
318	siRNA and shRNA screens advance key understanding of host factors required for HIV-1 replication. <i>Retrovirology</i> , 2009, 6, 78.	0.9	24
319	MicroRNA-Based Therapeutics for Cancer. <i>BioDrugs</i> , 2009, 23, 15-23.	2.2	140
320	Chapter 5 MicroRNA-Mediated Gene Silencing. <i>Progress in Molecular Biology and Translational Science</i> , 2009, 90, 187-210.	0.9	15
321	Antisense Inhibitors, Ribozymes, and siRNAs. <i>Clinics in Liver Disease</i> , 2009, 13, 375-390.	1.0	8
322	MicroRNA Interference Technologies. , 2009, , .		19
323	siRNA and miRNA Gene Silencing. <i>Methods in Molecular Biology</i> , 2009, , .	0.4	5
324	Antiviral Strategies. <i>Handbook of Experimental Pharmacology</i> , 2009, , .	0.9	3
325	RNA Interference Technologies and Therapeutics. <i>BioDrugs</i> , 2009, 23, 305-332.	2.2	42
326	A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. <i>Nucleic Acids Research</i> , 2009, 37, 2867-2881.	6.5	315
327	Intron-Mediated RNA Interference and microRNA Biogenesis. <i>Methods in Molecular Biology</i> , 2009, 487, 1-27.	0.4	34
328	Nucleic Acids-Based Therapeutics in the Battle Against Pathogenic Viruses. <i>Handbook of Experimental Pharmacology</i> , 2009, , 243-263.	0.9	36
329	Leveraging therapeutic potential of multi-targeted siRNA inhibitors. <i>Future Medicinal Chemistry</i> , 2009, 1, 1671-1681.	1.1	9

#	ARTICLE	IF	CITATIONS
330	Therapy for prion diseases: Insights from the use of RNA interference. <i>Prion</i> , 2009, 3, 121-128.	0.9	23
331	Does RNA interference provide new hope for control of chronic hepatitis B infection?. <i>Antiviral Therapy</i> , 2009, 14, 879-889.	0.6	11
332	Targeting Allergic Airway Diseases by siRNA: An Option for the Future?. <i>Current Molecular Medicine</i> , 2009, 9, 483-494.	0.6	5
333	Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease. <i>Current Gene Therapy</i> , 2009, 9, 375-388.	0.9	45
334	Hepatic Delivery of RNA Interference Activators for Therapeutic Application. <i>Current Gene Therapy</i> , 2009, 9, 91-103.	0.9	17
335	Future Challenges for Microsomal Transport Protein Inhibitors. <i>Current Vascular Pharmacology</i> , 2009, 7, 277-286.	0.8	43
336	RNAi Applications in Therapy Development for Neurodegenerative Disease. <i>Current Pharmaceutical Design</i> , 2009, 15, 3977-3991.	0.9	27
337	MicroRNAs and Ischemic Heart Disease: Towards a Better Comprehension of Pathogenesis, New Diagnostic Tools and New Therapeutic Targets. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2009, 4, 109-118.	1.5	50
338	Systemic Delivery and Quantification of Unformulated Interfering RNAs In Vivo. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1117-1129.	1.0	16
339	In Search of the Most Suitable Lentiviral shRNA System. <i>Current Gene Therapy</i> , 2009, 9, 192-211.	0.9	16
340	Targeting Matrix Metalloproteinases in Inflammatory Conditions. <i>Current Drug Targets</i> , 2009, 10, 1245-1254.	1.0	82
341	MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets. <i>Current Drug Targets</i> , 2010, 11, 801-811.	1.0	9
342	Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements. <i>Current Pharmaceutical Design</i> , 2010, 16, 2252-2268.	0.9	13
343	Recent Patents in Antiviral siRNAs. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2010, 5, 44-57.	0.5	4
344	Defining Features and Exploring Chemical Modifications to Manipulate RNAa Activity. <i>Current Pharmaceutical Biotechnology</i> , 2010, 11, 518-526.	0.9	67
345	Small Non-Coding RNAs as Novel Therapeutics. <i>Current Molecular Medicine</i> , 2010, 10, 361-368.	0.6	69
346	RNA Interference to Treat Enteroviral Disease: Current Status and Clinical Perspectives. <i>Current Molecular Medicine</i> , 2010, 10, 550-564.	0.6	2
347	MicroRNA Signatures in Neurological Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 177-185.	0.3	45

#	ARTICLE	IF	CITATIONS
348	RNA- and DNA- Based Therapies for Huntington's Disease. <i>Frontiers in Neuroscience</i> , 2010, , 225-253.	0.0	3
349	Nonviral Transfection of Mouse Calvarial Organ In Vitro Using Accell-Modified siRNA. <i>Plastic and Reconstructive Surgery</i> , 2010, 125, 494-501.	0.7	11
350	A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. <i>Blood</i> , 2010, 115, 1534-1544.	0.6	132
351	Delivery of siRNA Therapeutics: Barriers and Carriers. <i>AAPS Journal</i> , 2010, 12, 492-503.	2.2	653
352	Biogenesis and function of endogenous and exogenous siRNAs. <i>Wiley Interdisciplinary Reviews RNA</i> , 2010, 1, 117-131.	3.2	31
353	Engineering RNA for Targeted siRNA Delivery and Medical Application. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 650-666.	6.6	262
354	Post-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1390-1401.	6.6	29
355	Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. <i>Molecular BioSystems</i> , 2010, 6, 1143-61.	2.9	53
356	Methods in mammalian cell line engineering: from random mutagenesis to sequence-specific approaches. <i>Applied Microbiology and Biotechnology</i> , 2010, 88, 425-436.	1.7	59
357	MicroRNAs in Cardiovascular Diseases: Biology and Potential Clinical Applications. <i>Journal of Cardiovascular Translational Research</i> , 2010, 3, 256-270.	1.1	36
358	Protection of <i>Penaeus monodon</i> from Infection of White spot syndrome virus by DNA Construct Expressing Long Hairpin-RNA Against ICP11 Gene. <i>Indian Journal of Virology: an Official Organ of Indian Virological Society</i> , 2010, 21, 95-102.	0.7	9
359	Comparison of approaches for efficient gene silencing induced by microRNA-based short hairpin RNA and indicator gene expression. <i>Molecular Biology Reports</i> , 2010, 37, 1831-1839.	1.0	5
360	Prolonged gene silencing by combining siRNA nanogels and photochemical internalization. <i>Journal of Controlled Release</i> , 2010, 145, 281-288.	4.8	92
361	microRNA: Emerging therapeutic targets in acute ischemic diseases. , 2010, 125, 92-104.		166
362	RNAi and small interfering RNAs in human disease therapeutic applications. <i>Trends in Biotechnology</i> , 2010, 28, 570-579.	4.9	260
363	Therapeutic gene silencing strategies for polyglutamine disorders. <i>Trends in Genetics</i> , 2010, 26, 29-38.	2.9	23
364	RNA Interference inhibits Hepatitis B Virus of different genotypes in Vitro and in Vivo. <i>BMC Microbiology</i> , 2010, 10, 214.	1.3	23
365	Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. <i>BMC Neuroscience</i> , 2010, 11, 20.	0.8	73

#	ARTICLE	IF	CITATIONS
366	Inhibition of Hepatitis E virus replication using short hairpin RNA (shRNA). <i>Antiviral Research</i> , 2010, 85, 541-550.	1.9	17
367	Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus. <i>Antiviral Research</i> , 2010, 87, 307-317.	1.9	35
368	RNAi as a new therapeutic strategy against HCV. <i>Biotechnology Advances</i> , 2010, 28, 27-34.	6.0	30
369	Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook. <i>ChemMedChem</i> , 2010, 5, 328-349.	1.6	175
370	Therapeutic RNA manipulation in liver disease. <i>Hepatology</i> , 2010, 51, 1055-1061.	3.6	27
371	Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster. <i>Hepatology</i> , 2010, 52, 1877-1887.	3.6	42
372	Small noncoding RNAs: Biogenesis, function, and emerging significance in toxicology. <i>Journal of Biochemical and Molecular Toxicology</i> , 2010, 24, 195-216.	1.4	85
375	Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 765-770.	6.7	30
377	Proof of RNA Interference in Humans after Systemic Delivery of siRNAs. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 6258-6259.	7.2	8
378	Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. <i>Journal of Gene Medicine</i> , 2010, 12, 255-265.	1.4	47
379	Emerging role of small ribonucleic acids in gastrointestinal tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 173-185.	2.0	0
380	A direct comparison of strategies for combinatorial RNA interference. <i>BMC Molecular Biology</i> , 2010, 11, 77.	3.0	17
381	A status report on RNAi therapeutics. <i>Silence: A Journal of RNA Regulation</i> , 2010, 1, 14.	8.0	269
382	Non-coding RNAs: regulators of disease. <i>Journal of Pathology</i> , 2010, 220, 126-139.	2.1	906
383	Designing highly active siRNAs for therapeutic applications. <i>FEBS Journal</i> , 2010, 277, 4806-4813.	2.2	71
384	AAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based hairpins. <i>Gene Therapy</i> , 2010, 17, 486-493.	2.3	51
385	Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 57-67.	21.5	838
386	Targeting microRNAs in cancer: rationale, strategies and challenges. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 775-789.	21.5	1,308

#	ARTICLE	IF	CITATIONS
387	Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark period. <i>European Journal of Neuroscience</i> , 2010, 32, 1528-1536.	1.2	44
388	MicroRNAs in common diseases and potential therapeutic applications. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 102-107.	0.9	50
389	Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo. <i>Frontiers in Neural Circuits</i> , 2010, 3, 16.	1.4	76
390	Heme Oxygenase-1 in Tumor Biology and Therapy. <i>Current Drug Targets</i> , 2010, 11, 1551-1570.	1.0	224
391	Microrna Let-7: An Emerging Next-Generation Cancer Therapeutic. <i>Current Oncology</i> , 2010, 17, 70-80.	0.9	226
392	The Roles of Cyclin A2, B1, and B2 in Early and Late Mitotic Events. <i>Molecular Biology of the Cell</i> , 2010, 21, 3149-3161.	0.9	150
393	Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. <i>Nucleic Acids Research</i> , 2010, 38, 6652-6663.	6.5	32
394	Designing small multiple-target artificial RNAs. <i>Nucleic Acids Research</i> , 2010, 38, e140-e140.	6.5	36
395	RNA duplexes in transcriptional regulation. <i>Biomolecular Concepts</i> , 2010, 1, 285-296.	1.0	1
396	Quantitative analysis of conditional gene inactivation using rationally designed, tetracycline-controlled miRNAs. <i>Nucleic Acids Research</i> , 2010, 38, e168-e168.	6.5	26
397	Atypical transcription of microRNA gene fragments. <i>Nucleic Acids Research</i> , 2010, 38, 2775-2787.	6.5	12
398	From Stem Cells to Bone: Phenotype Acquisition, Stabilization, and Tissue Engineering in Animal Models. <i>ILAR Journal</i> , 2010, 51, 42-61.	1.8	36
399	K14 mRNA reprogramming for dominant epidermolysis bullosa simplex. <i>Human Molecular Genetics</i> , 2010, 19, 4715-4725.	1.4	55
400	Future Prospect of RNA Interference for Cancer Therapies. <i>Current Drug Targets</i> , 2010, 11, 345-360.	1.0	61
401	The Dicer Role of Dicer: Implications for RNAi Therapy. <i>Cancer Research</i> , 2010, 70, 2571-2574.	0.4	61
402	Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma. <i>Clinical Cancer Research</i> , 2010, 16, 4077-4083.	3.2	128
403	Novel RNA-based Strategies for Therapeutic Gene Silencing. <i>Molecular Therapy</i> , 2010, 18, 466-476.	3.7	116
404	Engineered RNA viral synthesis of microRNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11519-11524.	3.3	86

#	ARTICLE	IF	CITATIONS
405	Sequence-non-specific effects of RNA interference triggers and microRNA regulators. <i>Nucleic Acids Research</i> , 2010, 38, 1-16.	6.5	485
406	Combination of RNA interference and U1 inhibition leads to increased inhibition of gene expression. <i>Nucleic Acids Research</i> , 2010, 38, e136-e136.	6.5	18
407	RNAi-Based Strategies for Cyclooxygenase-2 Inhibition in Cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-11.	3.0	25
408	Minimal-length short hairpin RNAs: The relationship of structure and RNAi activity. <i>Rna</i> , 2010, 16, 106-117.	1.6	68
409	Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1373-1385.	2.4	38
410	Biomolecular engineering of intracellular switches in eukaryotes. <i>Journal of Drug Delivery Science and Technology</i> , 2010, 20, 163-169.	1.4	4
411	Human tRNA-derived small RNAs in the global regulation of RNA silencing. <i>Rna</i> , 2010, 16, 673-695.	1.6	583
412	Concurrent Suppression of Integrin β 5, Radixin, and RhoA Phenocopies the Effects of miR-31 on Metastasis. <i>Cancer Research</i> , 2010, 70, 5147-5154.	0.4	104
413	Pronuclear injection-based mouse targeted transgenesis for reproducible and highly efficient transgene expression. <i>Nucleic Acids Research</i> , 2010, 38, e198-e198.	6.5	53
414	Incentive Learning Underlying Cocaine-Seeking Requires mGluR5 Receptors Located on Dopamine D1 Receptor-Expressing Neurons. <i>Journal of Neuroscience</i> , 2010, 30, 11973-11982.	1.7	66
415	Possibilities for RNA Interference in Developing Hepatitis C Virus Therapeutics. <i>Viruses</i> , 2010, 2, 1647-1665.	1.5	6
416	Applications of RNA interference-based gene silencing in animal agriculture. <i>Reproduction, Fertility and Development</i> , 2010, 22, 47.	0.1	8
417	Computational Models of HIV-1 Resistance to Gene Therapy Elucidate Therapy Design Principles. <i>PLoS Computational Biology</i> , 2010, 6, e1000883.	1.5	14
418	FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E384-E393.	1.8	161
419	Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. <i>Cardiovascular Research</i> , 2010, 86, 353-364.	1.8	39
420	Gene Therapy with Helper-Dependent Adenoviral Vectors: Current Advances and Future Perspectives. <i>Viruses</i> , 2010, 2, 1886-1917.	1.5	44
421	Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. <i>Clinical Lipidology</i> , 2010, 5, 793-809.	0.4	13
422	β -Synuclein Expression in Rat Substantia Nigra Suppresses Phospholipase D2 Toxicity and Nigral Neurodegeneration. <i>Molecular Therapy</i> , 2010, 18, 1758-1768.	3.7	40

#	ARTICLE	IF	CITATIONS
423	Transgenic RNAi Applications in the Mouse. <i>Methods in Enzymology</i> , 2010, 477, 367-386.	0.4	7
424	Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice. <i>Molecular Therapy</i> , 2010, 18, 161-170.	3.7	39
425	Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs. <i>Artificial DNA, PNA & XNA</i> , 2010, 1, 17-26.	1.4	28
426	Isolated GH Deficiency Type II: Knockdown of the Harmful β 3GH Recovers wt-GH Secretion in Rat Tumor Pituitary Cells. <i>Endocrinology</i> , 2010, 151, 4400-4409.	1.4	13
427	Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 859-869.	2.4	16
428	Structure and activity of putative intronic miRNA promoters. <i>Rna</i> , 2010, 16, 495-505.	1.6	313
429	Transferrin Receptor-Targeted Liposomes Encapsulating anti-BCR-ABL siRNA or asODN for Chronic Myeloid Leukemia Treatment. <i>Bioconjugate Chemistry</i> , 2010, 21, 157-168.	1.8	82
430	Use of small RNAs for therapeutic gene silencing: risk versus benefit. <i>Drug Discovery Today: Technologies</i> , 2010, 7, e51-e57.	4.0	1
431	Intron-Mediated RNA Interference, Intronic MicroRNAs, and Applications. <i>Methods in Molecular Biology</i> , 2010, 629, 203-235.	0.4	27
432	Therapeutic Liver Reconstitution With Murine Cells Isolated Long After Death. <i>Gastroenterology</i> , 2010, 139, 1019-1029.	0.6	29
433	Regulatory RNA in Gene Therapy. , 2010, , 103-122.		1
434	Gene Silencing Mediated by Magnetic Lipospheres Tagged with Small Interfering RNA. <i>Nano Letters</i> , 2010, 10, 3914-3921.	4.5	66
435	Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. <i>Genes and Development</i> , 2010, 24, 992-1009.	2.7	706
436	Bioconjugation of Calcium Phosphosilicate Composite Nanoparticles for Selective Targeting of Human Breast and Pancreatic Cancers <i>In Vivo</i> . <i>ACS Nano</i> , 2010, 4, 1279-1287.	7.3	133
437	Posttranscriptional Regulation of MicroRNA Biogenesis in Animals. <i>Molecular Cell</i> , 2010, 38, 323-332.	4.5	507
438	Le monde complexe et mouvant des ARN. Seconde partie: les microARNs. <i>Immuno-Analyse Et Biologie Specialisee</i> , 2010, 25, 219-240.	0.0	1
439	Knockdown of Interleukin-2 by shRNA-Mediated RNA Interference Prolongs Liver Allograft Survival. <i>Journal of Surgical Research</i> , 2010, 159, 582-587.	0.8	12
440	Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites. <i>Journal of Hepatology</i> , 2010, 52, 817-826.	1.8	34

#	ARTICLE	IF	CITATIONS
441	Gene networks and the neuroendocrine regulation of puberty. <i>Molecular and Cellular Endocrinology</i> , 2010, 324, 3-11.	1.6	146
442	RNA interference as a gene knockdown technique. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1243-1251.	1.2	61
443	Riboregulators in kidney development and function. <i>Biochimie</i> , 2010, 92, 217-225.	1.3	15
444	Viral vector-mediated RNA interference. <i>Current Opinion in Pharmacology</i> , 2010, 10, 534-542.	1.7	122
445	Recent advances in the manipulation of murine gene expression and its utility for the study of human neurological disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 796-807.	1.8	10
446	U6 promoter-driven siRNA injection has nonspecific effects in zebrafish. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1363-1368.	1.0	14
447	Identification of sequence features that predict competition potency of siRNAs. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 92-97.	1.0	6
448	tRNALys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 640-646.	1.0	11
449	RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform. <i>Annual Review of Pharmacology and Toxicology</i> , 2010, 50, 259-293.	4.2	1,136
450	RNA interference: a chemist's perspective. <i>Chemical Society Reviews</i> , 2010, 39, 4169.	18.7	66
451	microRNA Biogenesis and its Impact on RNA Interference. , 2010, , 325-354.		1
452	Silencing Huntingtonâ€™s Disease Gene with RNAi. , 2010, , 131-160.		1
453	Selected Strategies for the Delivery of siRNA In Vitro and In Vivo. <i>RNA Technologies</i> , 2010, , 29-58.	0.2	14
454	mRNA Structure and its Effects on Posttranscriptional Gene Silencing. , 2010, , 255-275.		0
455	RNAi Treatment of HIV-1 Infection. , 2010, , 191-208.		0
456	Application of Dicer-Substrate siRNA in Pain Research. , 2010, , 161-190.		1
457	Strategies to Prevent siRNA-Triggered Cellular Toxicity. , 2010, , 93-106.		0
458	Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1347-1362.	1.5	38

#	ARTICLE	IF	CITATIONS
459	A Multifunctional Lentiviral-Based Gene Knockdown with Concurrent Rescue that Controls for Off-Target Effects of RNAi. <i>Genomics, Proteomics and Bioinformatics</i> , 2010, 8, 238-245.	3.0	40
460	Breaking down the barriers: siRNA delivery and endosome escape. <i>Journal of Cell Science</i> , 2010, 123, 1183-1189.	1.2	540
461	RNA Therapeutics. <i>Methods in Molecular Biology</i> , 2010, 629, v-vii.	0.4	5
462	Rat Genomics. <i>Methods in Molecular Biology</i> , 2010, , .	0.4	3
464	RNA interference therapy for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 927-936.	1.4	26
467	Non-coding RNAs: a key to future personalized molecular therapy?. <i>Genome Medicine</i> , 2010, 2, 12.	3.6	97
468	Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection. <i>Genome Medicine</i> , 2010, 2, 28.	3.6	15
469	RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 201-213.	1.4	38
470	AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 315-327.	1.4	28
471	The Regulatory Activities of Plant MicroRNAs: A More Dynamic Perspective. <i>Plant Physiology</i> , 2011, 157, 1583-1595.	2.3	92
472	Vigilance and Validation: Keys to Success in RNAi Screening. <i>ACS Chemical Biology</i> , 2011, 6, 47-60.	1.6	110
473	Caveat of RNAi in Plants: The Off-Target Effect. <i>Methods in Molecular Biology</i> , 2011, 744, 13-25.	0.4	76
474	The TRAF-Interacting Protein (TRIP) Is a Regulator of Keratinocyte Proliferation. <i>Journal of Investigative Dermatology</i> , 2011, 131, 349-357.	0.3	30
476	MicroRNAs in idiopathic pulmonary fibrosis. <i>Translational Research</i> , 2011, 157, 191-199.	2.2	274
477	Implication of miRNA in the diagnosis and treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1265-1275.	1.1	20
478	RNA Interference in Mammalian Cell Systems. <i>Hormone Research in Paediatrics</i> , 2011, 75, 63-69.	0.8	11
479	Development of advanced therapies based on viral vector-mediated overexpression of therapeutic molecules and knockdown of disease-related genes for Parkinson's disease. <i>Therapeutic Delivery</i> , 2011, 2, 37-50.	1.2	4
480	Targeted Therapies. , 2011, , .		4

#	ARTICLE	IF	CITATIONS
482	Methods for the Discovery and Characterization of G Protein-Coupled Receptors. <i>Neuromethods</i> , 2011, , ,	0.2	0
483	RNA surveillance—An emerging role for RNA regulatory networks in aging. <i>Ageing Research Reviews</i> , 2011, 10, 216-224.	5.0	17
484	A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference. <i>Cell</i> , 2011, 145, 145-158.	13.5	278
485	Rapid, cell-based toxicity screen of potentially therapeutic post-transcriptional gene silencing agents. <i>Experimental Eye Research</i> , 2011, 92, 328-337.	1.2	11
486	Role of microRNAs in hepatitis B virus replication and pathogenesis. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 678-685.	0.9	77
487	Adenovirus and miRNAs. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 660-667.	0.9	20
488	MicroRNA-like antivirals. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 746-755.	0.9	8
489	miRNA cassettes in viral vectors: Problems and solutions. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 732-745.	0.9	77
490	Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles. <i>Biochemical and Biophysical Research Communications</i> , 2011, 405, 204-209.	1.0	16
491	Characterisation and comparison of the chicken H1 RNA polymerase III promoter for short hairpin RNA expression. <i>Biochemical and Biophysical Research Communications</i> , 2011, 416, 194-198.	1.0	5
492	miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. <i>Clinical Investigation</i> , 2011, 1, 1637-1650.	0.0	8
493	Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay. <i>Molecular Cell</i> , 2011, 41, 733-746.	4.5	193
494	Viral RNAi Suppressor Reversibly Binds siRNA to Outcompete Dicer and RISC via Multiple Turnover. <i>Journal of Molecular Biology</i> , 2011, 408, 262-276.	2.0	25
495	Engineering Viruses For Gene Therapy. , 2011, , 17-33.		1
496	Toward a Durable Treatment of HIV-1 Infection Using RNA Interference. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 102, 141-163.	0.9	16
497	Therapeutic Oligonucleotides. <i>Methods in Molecular Biology</i> , 2011, 764, 1-15.	0.4	65
498	In Vivo Delivery of RNAi with Lipid-Based Nanoparticles. <i>Annual Review of Biomedical Engineering</i> , 2011, 13, 507-530.	5.7	156
499	Toxicity of Polymeric-Based Non-Viral Vector Systems for Pulmonary siRNA Application. , 0, , .		1

#	ARTICLE	IF	CITATIONS
500	The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. <i>Pathology</i> , 2011, 43, 657-671.	0.3	40
502	A Potential of microRNAs for High-Content Screening. <i>Journal of Nucleic Acids</i> , 2011, 2011, 1-15.	0.8	14
503	RNA Interference as Therapeutics for Hepatocellular Carcinoma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 106-115.	0.8	31
504	Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. <i>Journal of Clinical Investigation</i> , 2011, 121, 4850-4860.	3.9	376
505	Variables and Strategies in Development of Therapeutic Post-Transcriptional Gene Silencing Agents. <i>Journal of Ophthalmology</i> , 2011, 2011, 1-31.	0.6	7
506	Retinal Degenerations: Genetics, Mechanisms, and Therapies. <i>Journal of Ophthalmology</i> , 2011, 2011, 1-2.	0.6	1
507	A Molecular Toolbox for Rapid Generation of Viral Vectors to Up- or Down-Regulate Neuronal Gene Expression in vivo. <i>Frontiers in Molecular Neuroscience</i> , 2011, 4, 8.	1.4	33
508	Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain. <i>Frontiers in Molecular Neuroscience</i> , 2011, 4, 10.	1.4	19
509	MicroRNA Controlled Adenovirus Mediates Anti-Cancer Efficacy without Affecting Endogenous MicroRNA Activity. <i>PLoS ONE</i> , 2011, 6, e16152.	1.1	34
510	A Non-Specific Effect Associated with Conditional Transgene Expression Based on Cre-loxP Strategy in Mice. <i>PLoS ONE</i> , 2011, 6, e18778.	1.1	23
511	Identification of Allele-Specific RNAi Effectors Targeting Genetic Forms of Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e26194.	1.1	17
513	Liver-Directed Gene Therapy with Helper-Dependent Adenoviral Vectors: Current State of the Art and Future Challenges. <i>Current Pharmaceutical Design</i> , 2011, 17, 2488-2499.	0.9	15
514	Improving siRNA Bio-Distribution and Minimizing Side Effects. <i>Current Drug Metabolism</i> , 2011, 12, 11-23.	0.7	48
515	THE DISCOVERY OF RNA INTERFERENCE " GENE SILENCING BY DOUBLE-STRANDED RNA. , 2011, , 309-328.		1
516	From RNA interference technology to effective therapy: how far have we come and how far to go?. <i>Therapeutic Delivery</i> , 2011, 2, 1395-1406.	1.2	6
518	RNA Interference and Its Potential Applications to Chronic HBV Treatment: Results of a Phase I Safety and Tolerability Study. <i>Antiviral Therapy</i> , 2011, 16, 547-554.	0.6	23
519	Control of HBV replication by antiviral microRNAs transferred by lentiviral vectors for potential cell and gene therapy approaches. <i>Antiviral Therapy</i> , 2011, 17, 519-528.	0.6	13
520	Lmo Genes Regulate Behavioral Responses to Ethanol in <i>Drosophila melanogaster</i> and the Mouse. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, no-no.	1.4	37

#	ARTICLE	IF	CITATIONS
521	RNA interference in the clinic: challenges and future directions. <i>Nature Reviews Cancer</i> , 2011, 11, 59-67.	12.8	729
522	MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. <i>Nature Reviews Cancer</i> , 2011, 11, 849-864.	12.8	870
523	Current prospects for RNA interference-based therapies. <i>Nature Reviews Genetics</i> , 2011, 12, 329-340.	7.7	674
524	State-of-the-art gene-based therapies: the road ahead. <i>Nature Reviews Genetics</i> , 2011, 12, 316-328.	7.7	587
525	Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. <i>Nature Reviews Genetics</i> , 2011, 12, 341-355.	7.7	797
526	Competition for XPO5 binding between Dicer mRNA, pre-miRNA and viral RNA regulates human Dicer levels. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 323-327.	3.6	84
527	Efficient in vivo microRNA targeting of liver metastasis. <i>Oncogene</i> , 2011, 30, 1481-1488.	2.6	101
528	Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. <i>Gene Therapy</i> , 2011, 18, 666-673.	2.3	88
529	AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i. <i>Gene Therapy</i> , 2011, 18, 929-935.	2.3	14
530	RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors. <i>Gene Therapy</i> , 2011, 18, 953-960.	2.3	12
531	MicroRNA history: Discovery, recent applications, and next frontiers. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 717, 1-8.	0.4	351
532	Shielding the messenger (RNA): microRNA-based anticancer therapies. , 2011, 131, 18-32.		52
533	Breast cancer and microRNAs: therapeutic impact. <i>Breast</i> , 2011, 20, S63-S70.	0.9	87
534	Stem cell-based anti-HIV gene therapy. <i>Virology</i> , 2011, 411, 260-272.	1.1	47
535	Inhibition of highly pathogenic PRRSV replication in MARC-145 cells by artificial microRNAs. <i>Virology Journal</i> , 2011, 8, 491.	1.4	28
536	Schistosoma mansoni U6 gene promoter-driven short hairpin RNA induces RNA interference in human fibrosarcoma cells and schistosomules. <i>International Journal for Parasitology</i> , 2011, 41, 783-789.	1.3	27
537	Molecular strategies to design an escape-proof antiviral therapy. <i>Antiviral Research</i> , 2011, 92, 7-14.	1.9	34
538	Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection. <i>FEBS Letters</i> , 2011, 585, 1025-1030.	1.3	25

#	ARTICLE	IF	CITATIONS
539	RNA interference-produced autoregulation of inducible nitric oxide synthase expression. <i>FEBS Letters</i> , 2011, 585, 2488-2492.	1.3	6
540	The endogenous siRNA pathway in <i>Drosophila</i> impacts stress resistance and lifespan by regulating metabolic homeostasis. <i>FEBS Letters</i> , 2011, 585, 3079-3085.	1.3	47
541	Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silencing and intracellular imaging. <i>Biomaterials</i> , 2011, 32, 7978-7987.	5.7	93
542	A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. <i>Brain Research</i> , 2011, 1386, 15-24.	1.1	37
543	An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. <i>Brain Research</i> , 2011, 1395, 94-107.	1.1	97
544	New therapeutic targets for amyotrophic lateral sclerosis. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 127-143.	1.5	18
545	Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. <i>Nature</i> , 2011, 480, 547-551.	13.7	1,603
546	MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma. <i>Cancer Research</i> , 2011, 71, 5214-5224.	0.4	358
547	Chemical Modification of Small Interfering RNA. <i>Methods in Molecular Biology</i> , 2011, 721, 77-103.	0.4	49
548	Using drug-excipient interactions for siRNA delivery. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1210-1226.	6.6	41
549	MicroRNAs and Cancer Therapeutics. <i>Pharmaceutical Research</i> , 2011, 28, 3043-3049.	1.7	25
550	Antiviral RNAi: Translating Science Towards Therapeutic Success. <i>Pharmaceutical Research</i> , 2011, 28, 2966-2982.	1.7	18
551	The Therapeutic Potential of MicroRNAs: Disease Modulators and Drug Targets. <i>Pharmaceutical Research</i> , 2011, 28, 3016-3029.	1.7	67
552	RNA Interference and Cancer Therapy. <i>Pharmaceutical Research</i> , 2011, 28, 2983-2995.	1.7	131
553	Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA. <i>Pharmaceutical Research</i> , 2011, 28, 2996-3015.	1.7	169
554	The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma?. <i>Journal of Neuro-Oncology</i> , 2011, 103, 429-436.	1.4	32
555	Efficient mammalian germline transgenesis by cis-enhanced Sleeping Beauty transposition. <i>Transgenic Research</i> , 2011, 20, 29-45.	1.3	31
556	RNAi: a potential new class of therapeutic for human genetic disease. <i>Human Genetics</i> , 2011, 130, 583-605.	1.8	89

#	ARTICLE	IF	CITATIONS
557	Personalized Cancer Approach: Using RNA Interference Technology. <i>World Journal of Surgery</i> , 2011, 35, 1700-1714.	0.8	9
558	The sense strand pre-cleaved RNA duplex mediates an efficient RNA interference with less off-target and immune response effects. <i>Applied Microbiology and Biotechnology</i> , 2011, 90, 583-589.	1.7	5
559	RNA Interference in Pigs: Comparison of RNAi Test Systems and Expression Vectors. <i>Molecular Biotechnology</i> , 2011, 48, 38-48.	1.3	12
560	Construction of permanently inducible miRNA-based expression vectors using site-specific recombinases. <i>BMC Biotechnology</i> , 2011, 11, 107.	1.7	4
561	The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. <i>Silence: A Journal of RNA Regulation</i> , 2011, 2, 8.	8.0	65
562	Countering hepatitis B virus infection using RNAi: how far are we from the clinic?. <i>Reviews in Medical Virology</i> , 2011, 21, 383-396.	3.9	25
563	Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease. <i>Journal of Gene Medicine</i> , 2011, 13, 188-197.	1.4	16
564	Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. <i>EMBO Molecular Medicine</i> , 2011, 3, 118-128.	3.3	72
565	Inducible and reversible breaching of the blood brain barrier by RNAi. <i>EMBO Molecular Medicine</i> , 2011, 3, 186-188.	3.3	2
566	The modification of siRNA with 3 ^{â€²} cholesterol to increase nuclease protection and suppression of native mRNA by select siRNA polyplexes. <i>Biomaterials</i> , 2011, 32, 1404-1411.	5.7	37
567	Using non-coding small RNAs to develop therapies for Huntington's disease. <i>Gene Therapy</i> , 2011, 18, 1139-1149.	2.3	37
568	Current progress and challenges in HIV gene therapy. <i>Future Virology</i> , 2011, 6, 1319-1328.	0.9	13
569	When Cellular Networks Run Out of Control. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 102, 165-242.	0.9	15
571	AAV6-mediated Systemic shRNA Delivery Reverses Disease in a Mouse Model of Facioscapulohumeral Muscular Dystrophy. <i>Molecular Therapy</i> , 2011, 19, 2055-2064.	3.7	43
572	Apolipoprotein B Knockdown by AAV-delivered shRNA Lowers Plasma Cholesterol in Mice. <i>Molecular Therapy</i> , 2011, 19, 731-740.	3.7	28
573	Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease. <i>Molecular Therapy</i> , 2011, 19, 2169-2177.	3.7	68
574	Implications of RNA virus-produced miRNAs. <i>RNA Biology</i> , 2011, 8, 190-194.	1.5	23
575	Sensor and Sensitivity: A Screen for Elite shRNAs. <i>Molecular Therapy</i> , 2011, 19, 823-825.	3.7	2

#	ARTICLE	IF	CITATIONS
576	Small Interfering RNA for Effective Cancer Therapies. Mini-Reviews in Medicinal Chemistry, 2011, 11, 114-124.	1.1	11
577	Cardiac Gene Transfer of Short Hairpin RNA Directed Against Phospholamban Effectively Knocks Down Gene Expression but Causes Cellular Toxicity in Canines. Human Gene Therapy, 2011, 22, 969-977.	1.4	43
578	Involvement of MicroRNAs in Dioxin-Induced Liver Damage in the Mouse. Toxicological Sciences, 2011, 122, 457-465.	1.4	48
579	RNAi medicine for the brain: progresses and challenges. Human Molecular Genetics, 2011, 20, R21-R27.	1.4	64
580	RNAi in Xenopus: look before you leap. Genes and Development, 2011, 25, 1105-1108.	2.7	2
581	Gene therapy for alpha-1 antitrypsin deficiency. Human Molecular Genetics, 2011, 20, R87-R92.	1.4	43
582	Effects of HBV Genetic Variability on RNAi Strategies. Hepatitis Research and Treatment, 2011, 2011, 1-8.	2.0	6
583	Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma. Sarcoma, 2011, 2011, 1-11.	0.7	18
584	RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice. Molecular Pharmacology, 2011, 79, 953-963.	1.0	44
585	Modified siRNA Structure With a Single Nucleotide Bulge Overcomes Conventional siRNA-mediated Off-target Silencing. Molecular Therapy, 2011, 19, 1676-1687.	3.7	37
586	RNA interference in mammals: behind the screen. Briefings in Functional Genomics, 2011, 10, 215-226.	1.3	27
588	Combination of the somatic cell nuclear transfer method and RNAi technology for the production of a prion gene-knockdown calf using plasmid vectors harboring the U6 or tRNA promoter. Prion, 2011, 5, 39-46.	0.9	14
589	Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14258-14263.	3.3	64
590	A Foamy Virus Vector System for Stable and Efficient RNAi Expression in Mammalian Cells. Human Gene Therapy, 2011, 22, 1293-1303.	1.4	2
591	Constitutive Expression of Short Hairpin RNA in Vivo Triggers Buildup of Mature Hairpin Molecules. Human Gene Therapy, 2011, 22, 1483-1497.	1.4	11
592	Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. Cancer Gene Therapy, 2011, 18, 587-597.	2.2	15
593	The Development of RNA Interference Therapeutics. Nucleic Acid Therapeutics, 2011, 21, 371-372.	2.0	7
594	Structural Diversity Repertoire of Gene Silencing Small Interfering RNAs. Nucleic Acid Therapeutics, 2011, 21, 125-131.	2.0	24

#	ARTICLE	IF	CITATIONS
595	Suppression of transforming growth factor β 21 in lung alveolar epithelium-derived cells using adeno-associated virus type 2/5 vectors to carry short hairpin RNA. <i>Experimental Lung Research</i> , 2011, 37, 175-185.	0.5	2
596	Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing. <i>Nucleic Acids Research</i> , 2011, 39, 2981-2994.	6.5	130
597	Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H2112-H2121.	1.5	20
598	Carbon Nanotube-Metal Contact. , 2012, , 388-391.		1
599	Potential molecular targets for Ewing's sarcoma therapy. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2012, 33, 195-202.	0.1	2
600	Prospect of Induced Pluripotent Stem Cell Genetic Repair to Cure Genetic Diseases. <i>Stem Cells International</i> , 2012, 2012, 1-7.	1.2	6
601	RNA therapy for polyglutamine neurodegenerative diseases. <i>Expert Reviews in Molecular Medicine</i> , 2012, 14, e3.	1.6	13
602	In Vivo Delivery of Cytoplasmic RNA Virus-derived miRNAs. <i>Molecular Therapy</i> , 2012, 20, 367-375.	3.7	45
603	Antiviral Effects of Small Interfering RNA Simultaneously Inducing RNA Interference and Type 1 Interferon in Coxsackievirus Myocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3516-3523.	1.4	8
604	Inducible and reversible regulation of endogenous gene in mouse. <i>Nucleic Acids Research</i> , 2012, 40, e166-e166.	6.5	12
605	MicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment. <i>Experimental Biology and Medicine</i> , 2012, 237, 227-235.	1.1	26
606	Epigenetics and stroke risk – beyond the static DNA code. <i>Advances in Genomics and Genetics</i> , 2012, , 67.	0.8	2
608	All for One, One for All: New Combinatorial RNAi Therapies Combat Hepatitis C Virus Evolution. <i>Molecular Therapy</i> , 2012, 20, 1661-1663.	3.7	8
609	miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications. <i>Current Pharmaceutical Design</i> , 2012, 19, 1301-1310.	0.9	4
610	HIV Develops Indirect Cross-resistance to Combinatorial RNAi Targeting Two Distinct and Spatially Distant Sites. <i>Molecular Therapy</i> , 2012, 20, 840-848.	3.7	25
611	Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA Profiles. <i>Molecular Therapy</i> , 2012, 20, 590-600.	3.7	105
612	AAV-Based RNAi Silencing of NADPH Oxidase gp91 ^{phox} Attenuates Cold-Induced Cardiovascular Dysfunction. <i>Human Gene Therapy</i> , 2012, 23, 1016-1026.	1.4	20
614	Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model. <i>Molecular Therapy</i> , 2012, 20, 1737-1749.	3.7	46

#	ARTICLE	IF	CITATIONS
615	Specific Inhibition of SRC Kinase Impairs Malignant Glioma Growth In Vitro and In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e19.	2.3	6
616	Small RNA-Mediated Epigenetic Myostatin Silencing. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e23.	2.3	23
617	Intrathecal shRNA-AAV9 Inhibits Target Protein Expression in the Spinal Cord and Dorsal Root Ganglia of Adult Mice. <i>Human Gene Therapy Methods</i> , 2012, 23, 119-127.	2.1	21
619	Therapeutic modulation of miRNA for the treatment of proinflammatory lung diseases. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 359-368.	2.0	35
620	Characterization of an HIV-Targeted Transcriptional Gene-Silencing RNA in Primary Cells. <i>Human Gene Therapy</i> , 2012, 23, 473-483.	1.4	37
621	Using Lentiviral Vectors as Delivery Vehicles for Gene Therapy. <i>Neuromethods</i> , 2012, , 69-96.	0.2	7
622	Artificial mirtron-mediated gene knockdown: Functional DMPK silencing in mammalian cells. <i>Rna</i> , 2012, 18, 1328-1337.	1.6	13
623	Mechanism of Repeat-Associated MicroRNAs in Fragile X Syndrome. <i>Neural Plasticity</i> , 2012, 2012, 1-10.	1.0	13
624	Advances in Induced Pluripotent Stem Cell Technologies. <i>Stem Cells International</i> , 2012, 2012, 1-1.	1.2	0
625	In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1364-1375.	1.4	12
626	Increased in vivo inhibition of gene expression by combining RNA interference and U1 inhibition. <i>Nucleic Acids Research</i> , 2012, 40, e8-e8.	6.5	16
627	Expression determinants of mammalian argonaute proteins in mediating gene silencing. <i>Nucleic Acids Research</i> , 2012, 40, 3704-3713.	6.5	35
628	Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224. <i>Nucleic Acids Research</i> , 2012, 40, 9863-9875.	6.5	37
629	Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling. <i>Journal of Visualized Experiments</i> , 2012, , .	0.2	22
630	Induction of Apoptosis and Sensitization of Head and Neck Squamous Carcinoma Cells to Cisplatin by Targeting Survivin Gene Expression. <i>Current Gene Therapy</i> , 2012, 12, 444-453.	0.9	23
631	In Vivo, Cardiac-Specific Knockdown of a Target Protein, Malic Enzyme- 1, in Rat via Adenoviral Delivery of DNA for Non-Native miRNA. <i>Current Gene Therapy</i> , 2012, 12, 454-462.	0.9	10
632	Patents Review in siRNA Delivery for Pulmonary Disorders. <i>Recent Patents on Drug Delivery and Formulation</i> , 2012, 6, 45-65.	2.1	5
633	RNAi-based Gene Therapy for Dominant Limb Girdle Muscular Dystrophies. <i>Current Gene Therapy</i> , 2012, 12, 307-314.	0.9	8

#	ARTICLE	IF	CITATIONS
634	MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. <i>Oncology Reports</i> , 2012, 28, 1013-1021.	1.2	92
635	The role of microRNAs in HIV-1 pathogenesis and therapy. <i>Aids</i> , 2012, 26, 1325-1334.	1.0	34
636	MicroRNAs in Genetic Disease: Rethinking the Dosage. <i>Current Gene Therapy</i> , 2012, 12, 292-300.	0.9	10
637	The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. <i>Antiviral Therapy</i> , 2012, 17, 213-225.	0.6	45
639	Considering RNAi experimental design in parasitic helminths. <i>Parasitology</i> , 2012, 139, 589-604.	0.7	40
640	Polysaccharides as Nanomaterials for Therapeutics. , 2012, , 139-178.		0
641	RNAi as New Class of Nanomedicines. , 2012, , 179-214.		0
642	MicroRNAs Regulated by Adiponectin as Novel Targets for Controlling Adipose Tissue Inflammation. <i>Endocrinology</i> , 2012, 153, 5285-5296.	1.4	48
643	Generation of Hairpin-Based RNAi Vectors for Biological and Therapeutic Application. <i>Methods in Enzymology</i> , 2012, 507, 275-296.	0.4	40
644	A genome-wide transgenic resource for conditional expression of Drosophila microRNAs. <i>Development (Cambridge)</i> , 2012, 139, 2821-2831.	1.2	82
645	Model systems of genetically modified platelets. <i>Blood</i> , 2012, 119, 1634-1642.	0.6	19
646	Interference: an alterNATIVE therapy following acute myocardial infarction. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 635-645.	4.0	8
647	Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA. <i>Pharmaceuticals</i> , 2012, 5, 61-78.	1.7	16
648	Molecular Pathways: MicroRNAs as Cancer Therapeutics. <i>Clinical Cancer Research</i> , 2012, 18, 4234-4239.	3.2	62
649	The Loop Position of shRNAs and Pre-miRNAs Is Critical for the Accuracy of Dicer Processing InÂVivo. <i>Cell</i> , 2012, 151, 900-911.	13.5	266
650	RNA interference against repulsive guidance molecule A improves axon sprout and neural function recovery of rats after MCAO/reperfusion. <i>Experimental Neurology</i> , 2012, 238, 235-242.	2.0	24
651	RNA Interference with Special Reference to Combating Viruses of Crustacea. <i>Indian Journal of Virology: an Official Organ of Indian Virological Society</i> , 2012, 23, 226-243.	0.7	13
652	Functional Importance of Dicer Protein in the Adaptive Cellular Response to Hypoxia. <i>Journal of Biological Chemistry</i> , 2012, 287, 29003-29020.	1.6	126

#	ARTICLE	IF	CITATIONS
653	Quantitative functions of Argonaute proteins in mammalian development. <i>Genes and Development</i> , 2012, 26, 693-704.	2.7	153
654	The biogenesis and characterization of mammalian microRNAs of mirtron origin. <i>Nucleic Acids Research</i> , 2012, 40, 438-448.	6.5	86
655	Single siRNA Nanocapsules for Enhanced RNAi Delivery. <i>Journal of the American Chemical Society</i> , 2012, 134, 13542-13545.	6.6	60
656	Crosstalk between TGF- β signaling and the microRNA machinery. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 382-393.	4.0	196
657	A pipeline for the generation of shRNA transgenic mice. <i>Nature Protocols</i> , 2012, 7, 374-393.	5.5	146
658	Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). <i>Gut</i> , 2012, 61, 1330-1339.	6.1	150
659	Design and quality control of short interfering RNA. <i>Molecular Biology</i> , 2012, 46, 739-754.	0.4	2
660	Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100. <i>BMC Biotechnology</i> , 2012, 12, 42.	1.7	20
661	MicroRNAs and hepatitis C virus: Toward the end of miR-122 supremacy. <i>Virology Journal</i> , 2012, 9, 109.	1.4	29
662	Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct. <i>Virology Journal</i> , 2012, 9, 118.	1.4	21
663	Isolated Growth Hormone Deficiency Type 2: From Gene to Therapy. <i>Endocrine Development</i> , 2012, 23, 109-120.	1.3	6
664	The Business of RNAi Therapeutics in 2012. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e8.	2.3	84
665	Capacitive MEMS Switches. , 2012, , 363-374.		0
666	Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. <i>International Journal of Nanomedicine</i> , 2012, 7, 3637.	3.3	151
667	Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1738-1748.	6.6	75
668	Polycation-based nanoparticle delivery of RNAi therapeutics: Adverse effects and solutions. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1717-1729.	6.6	136
669	RNAi-based nanomedicines for targeted personalized therapy. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1508-1521.	6.6	147
670	PEI protected aptamer molecular probes for contrast-enhanced in vivo cancer imaging. <i>Biomaterials</i> , 2012, 33, 7810-7817.	5.7	47

#	ARTICLE	IF	CITATIONS
671	Gelatin nanospheres incorporating siRNA for controlled intracellular release. <i>Biomaterials</i> , 2012, 33, 9097-9104.	5.7	69
672	New targets for treatment against HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 505-515.	1.0	1
673	Competition between Small RNAs: A Quantitative View. <i>Biophysical Journal</i> , 2012, 102, 1712-1721.	0.2	41
674	Gene targeting in primary human trophoblasts. <i>Placenta</i> , 2012, 33, 754-762.	0.7	7
675	RNA interference in <i>Pratylenchus coffeae</i> : Knock down of Pc-pat-10 and Pc-unc-87 impedes migration. <i>Molecular and Biochemical Parasitology</i> , 2012, 186, 51-59.	0.5	32
676	RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy. <i>Molecular Therapy</i> , 2012, 20, 1417-1423.	3.7	101
677	New competition in RNA regulation. <i>Nature Biotechnology</i> , 2012, 30, 58-59.	9.4	12
678	A competitive cell growth assay for the detection of subtle effects of gene transduction on cell proliferation. <i>Gene Therapy</i> , 2012, 19, 1058-1064.	2.3	47
679	MicroRNAs in Rheumatoid Arthritis. <i>BioDrugs</i> , 2012, 26, 131-141.	2.2	89
680	Induction of Somatic Cell Reprogramming Using the MicroRNA miR-302. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 111, 83-107.	0.9	14
681	Chitosan Nanoparticles. , 2012, , 427-433.		0
682	The role and clinical implications of microRNAs in hepatocellular carcinoma. <i>Science China Life Sciences</i> , 2012, 55, 906-919.	2.3	36
684	Developing microRNA Therapeutics: Approaching the Unique Complexities. <i>Nucleic Acid Therapeutics</i> , 2012, 22, 213-225.	2.0	52
685	MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 314-319.	2.0	38
687	Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70. <i>Virology Journal</i> , 2012, 9, 275.	1.4	11
688	Prenatal Exposure to TCDD Triggers Significant Modulation of microRNA Expression Profile in the Thymus That Affects Consequent Gene Expression. <i>PLoS ONE</i> , 2012, 7, e45054.	1.1	63
689	Detrimental Effects of RNAi: A Cautionary Note on Its Use in <i>Drosophila</i> Ageing Studies. <i>PLoS ONE</i> , 2012, 7, e45367.	1.1	24
690	Dissecting Systemic RNA Interference in the Red Flour Beetle <i>Tribolium castaneum</i> : Parameters Affecting the Efficiency of RNAi. <i>PLoS ONE</i> , 2012, 7, e47431.	1.1	174

#	ARTICLE	IF	CITATIONS
691	Recent Patents on MicroRNA-Induced Pluripotent Stem Cell Generation. Recent Patents on Regenerative Medicine, 2012, 3, 5-16.	0.4	0
692	Efficient Silencing of Hepatitis B Virus by Helper-dependent Adenovirus Vector-mediated Delivery of Artificial Antiviral Primary Micro RNAs. MicroRNA (Sharjah, United Arab Emirates), 2012, 1, 19-25.	0.6	8
693	Silencing disease genes in the laboratory and the clinic. Journal of Pathology, 2012, 226, 365-379.	2.1	349
694	Mirtrons, an emerging class of atypical miRNA. Wiley Interdisciplinary Reviews RNA, 2012, 3, 617-632.	3.2	77
695	Gene Therapy for Heart Failure. Circulation Research, 2012, 110, 777-793.	2.0	130
696	Adeno-associated virus-delivered polycistronic microRNA clusters for knockdown of vascular endothelial growth factor <i>in vivo</i> . Journal of Gene Medicine, 2012, 14, 328-338.	1.4	40
697	Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO1 but induce an interferon response and cytotoxicity in central nervous system neurones. Journal of Gene Medicine, 2012, 14, 299-315.	1.4	17
698	MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Molecular Medicine, 2012, 4, 143-159.	3.3	1,481
699	Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles. Molecular Therapy, 2012, 20, 513-524.	3.7	231
700	Mechanism of MicroRNA-Mediated Global DNA Demethylation in Human iPS Cells. , 2012, , 117-134.		0
701	Illuminating the Gateway of Gene Silencing: Perspective of RNA Interference Technology in Clinical Therapeutics. Molecular Biotechnology, 2012, 51, 289-302.	1.3	5
702	Lentiviral vectors for cutaneous RNA managing. Experimental Dermatology, 2012, 21, 162-170.	1.4	7
703	Combined preconditioning and <i>in vivo</i> chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow. Experimental Hematology, 2012, 40, 3-13.e3.	0.2	14
704	Probing gene function in thymic epithelial cells. European Journal of Cell Biology, 2012, 91, 24-30.	1.6	5
705	A dynamic perspective of RNAi library development. Trends in Biotechnology, 2012, 30, 206-215.	4.9	27
706	Use of RNA interference to minimize ischemia reperfusion injury. Transplantation Reviews, 2012, 26, 140-155.	1.2	13
707	Altering the immune response with lipid-based nanoparticles. Journal of Controlled Release, 2012, 161, 600-608.	4.8	108
708	The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines <i>in vitro</i> and <i>in vivo</i> . International Journal of Cancer, 2012, 130, 1925-1936.	2.3	33

#	ARTICLE	IF	CITATIONS
709	MicroRNAs in adipose tissue: their role in adipogenesis and obesity. <i>International Journal of Obesity</i> , 2013, 37, 325-332.	1.6	141
710	Regulation of microRNA biogenesis and turnover by animals and their viruses. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 3525-3544.	2.4	76
711	Downregulation of human CCR5 gene expression with artificial microRNAs. <i>Molecular Biology</i> , 2013, 47, 419-428.	0.4	7
712	Construction of multiple shRNAs expression vector that inhibits FUT1 gene expression and production of the transgenic SCNT embryos in vitro. <i>Molecular Biology Reports</i> , 2013, 40, 2243-2252.	1.0	2
713	C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. <i>Applied & Translational Genomics</i> , 2013, 2, 3-16.	2.1	84
714	Trinucleotide Repeat Protocols. <i>Methods in Molecular Biology</i> , 2013, , .	0.4	3
715	DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases. , 2013, , .		8
716	RNAi for Insect Control: Current Perspective and Future Challenges. <i>Applied Biochemistry and Biotechnology</i> , 2013, 171, 847-873.	1.4	116
718	MicroRNA Protocols. <i>Methods in Molecular Biology</i> , 2013, , .	0.4	2
719	Towards microRNA-based therapeutics for diabetic nephropathy. <i>Diabetologia</i> , 2013, 56, 444-456.	2.9	29
720	A Novel Method for the Quantification of Adeno-Associated Virus Vectors for RNA Interference Applications Using Quantitative Polymerase Chain Reaction and Purified Genomic Adeno-Associated Virus DNA as a Standard. <i>Human Gene Therapy Methods</i> , 2013, 24, 355-363.	2.1	11
721	Gene-Based Therapy for Alpha-1 Antitrypsin Deficiency. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 44-49.	0.7	47
722	Accelerating Cancer Modeling with RNAi and Nongermine Genetically Engineered Mouse Models. <i>Cold Spring Harbor Protocols</i> , 2013, 2013, pdb.top069856.	0.2	17
723	Poly(aminoether)â€“Gold Nanorod Assemblies for shRNA Plasmid-Induced Gene Silencing. <i>Molecular Pharmaceutics</i> , 2013, 10, 4107-4119.	2.3	21
724	Cardiovascular RNA Interference Therapy. <i>Circulation Research</i> , 2013, 113, 588-602.	2.0	35
725	Rational design of microRNAâ€“siRNA chimeras for multifunctional target suppression. <i>Rna</i> , 2013, 19, 1745-1754.	1.6	10
726	siRNA Delivery for the treatment of ovarian cancer. <i>Methods</i> , 2013, 63, 95-100.	1.9	18
727	mi<scp>RNA</scp>s and <scp>HIV</scp>: unforeseen determinants of hostâ€“pathogen interaction. <i>Immunological Reviews</i> , 2013, 254, 265-280.	2.8	37

#	ARTICLE	IF	CITATIONS
728	Intraperitoneal Administration of AAV9-shRNA Inhibits Target Gene Expression in the Dorsal Root Ganglia of Neonatal Mice. <i>Molecular Pain</i> , 2013, 9, 1744-8069-9-36.	1.0	19
729	MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. <i>Journal of Biomedical Science</i> , 2013, 20, 99.	2.6	66
730	Therapeutic Application of MicroRNAs in Cancer. <i>Advances in Delivery Science and Technology</i> , 2013, , 299-314.	0.4	2
731	Progress in microRNA delivery. <i>Journal of Controlled Release</i> , 2013, 172, 962-974.	4.8	517
732	Clinical translation of RNAi-based treatments for respiratory diseases. <i>Drug Delivery and Translational Research</i> , 2013, 3, 84-99.	3.0	6
733	Doxycycline-Dependent Inducible and Reversible RNA Interference Mediated by a Single Lentivirus Vector. <i>Bioscience, Biotechnology and Biochemistry</i> , 2013, 77, 776-781.	0.6	10
734	Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection. <i>Biochemical Journal</i> , 2013, 455, 133-147.	1.7	45
735	Preclinical Evaluation of An Anti-HCV miRNA Cluster for Treatment of HCV Infection. <i>Molecular Therapy</i> , 2013, 21, 588-601.	3.7	25
736	siRNA-based therapeutic approaches for rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2013, 9, 56-62.	3.5	43
737	Mechanism and Method for Generating Tumor-Free iPS Cells Using Intronic MicroRNA miR-302 Induction. <i>Methods in Molecular Biology</i> , 2013, 936, 295-312.	0.4	32
738	MicroRNA biogenesis: regulating the regulators. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2013, 48, 51-68.	2.3	261
739	Systems-level analysis of host-pathogen interaction using RNA interference. <i>New Biotechnology</i> , 2013, 30, 308-313.	2.4	0
740	RNA viruses and the host microRNA machinery. <i>Nature Reviews Microbiology</i> , 2013, 11, 169-180.	13.6	121
741	Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2013, 1829, 455-468.	0.9	36
742	An Optimized microRNA Backbone for Effective Single-Copy RNAi. <i>Cell Reports</i> , 2013, 5, 1704-1713.	2.9	563
743	Genetic Modification of Mouse Bone Marrow by Lentiviral Vector-Mediated Delivery of Hypoxanthine-Guanine Phosphoribosyltransferase Short Hairpin RNA Confers Chemoprotection Against 6-Thioguanine Cytotoxicity. <i>Transplantation Proceedings</i> , 2013, 45, 2040-2044.	0.3	8
744	Organic small hairpin RNAs (OshR): A do-it-yourself platform for transgene-based gene silencing. <i>Methods</i> , 2013, 63, 101-109.	1.9	1
745	Variation in vasopressin receptor (Avpr1a) expression creates diversity in behaviors related to monogamy in prairie voles. <i>Hormones and Behavior</i> , 2013, 63, 518-526.	1.0	89

#	ARTICLE	IF	CITATIONS
746	Improving adenovirus vector-mediated RNAi efficiency by lacking the expression of virus-associated RNAs. <i>Virus Research</i> , 2013, 178, 357-363.	1.1	17
747	RNA helicase A is not required for RISC activity. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2013, 1829, 1092-1101.	0.9	10
748	RNA Interference Pathways and Therapeutic Exploitation. <i>Advances in Delivery Science and Technology</i> , 2013, , 1-29.	0.4	0
749	Dicer Deficiency Reveals MicroRNAs Predicted to Control Gene Expression in the Developing Adrenal Cortex. <i>Molecular Endocrinology</i> , 2013, 27, 754-768.	3.7	27
750	siRNA Design Principles and Off-Target Effects. <i>Methods in Molecular Biology</i> , 2013, 986, 59-71.	0.4	40
751	Drug Delivery Systems for the Treatment of Ischemic Stroke. <i>Pharmaceutical Research</i> , 2013, 30, 2429-2444.	1.7	46
752	A Direct In Vivo RNAi Screen Identifies MKK4 as a Key Regulator of Liver Regeneration. <i>Cell</i> , 2013, 153, 389-401.	13.5	127
755	RNAi as Antiviral Therapy: The HIV-1 Case. <i>Advances in Delivery Science and Technology</i> , 2013, , 221-242.	0.4	0
761	Targeting long non-coding RNAs in cancers: Progress and prospects. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1895-1910.	1.2	439
762	Lentiviral-Mediated Gene Transfer of siRNAs for the Treatment of Huntington's Disease. <i>Methods in Molecular Biology</i> , 2013, 1010, 95-109.	0.4	4
763	Emerging Roles for miRNAs in the Development, Diagnosis, and Treatment of Diabetic Nephropathy. <i>Current Diabetes Reports</i> , 2013, 13, 582-591.	1.7	20
764	Chitosan for Gene Delivery and Orthopedic Tissue Engineering Applications. <i>Molecules</i> , 2013, 18, 5611-5647.	1.7	133
765	Molecular dissection of human Argonaute proteins by DNA shuffling. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 818-826.	3.6	74
766	Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 891-901.	6.6	77
767	Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 1169-1180.	1.7	125
768	Hypoxia as a target for tissue specific gene therapy. <i>Journal of Controlled Release</i> , 2013, 172, 484-494.	4.8	59
769	Characterization of Zebrafish Polymerase III Promoters for the Expression of Short-Hairpin RNA Interference Molecules. <i>Zebrafish</i> , 2013, 10, 472-479.	0.5	12
770	Inhibition of Dengue Virus 2 Replication by Artificial MicroRNAs Targeting the Conserved Regions. <i>Nucleic Acid Therapeutics</i> , 2013, 23, 244-252.	2.0	30

#	ARTICLE	IF	CITATIONS
772	Short Hairpin RNA-Mediated Gene Silencing. <i>Methods in Molecular Biology</i> , 2013, 942, 205-232.	0.4	83
773	Bifunctional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application. <i>Methods in Molecular Biology</i> , 2013, 942, 259-278.	0.4	9
774	The Design, Preparation, and Evaluation of Asymmetric Small Interfering RNA for Specific Gene Silencing in Mammalian Cells. <i>Methods in Molecular Biology</i> , 2013, 942, 135-152.	0.4	3
775	Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. <i>Nucleic Acids Research</i> , 2013, 41, e199-e199.	6.5	53
776	The New Genetics and Natural versus Artificial Genetic Modification. <i>Entropy</i> , 2013, 15, 4748-4781.	1.1	12
777	Fluctuation of Global Gene Expression by Endogenous miRNA Response to the Introduction of an Exogenous miRNA. <i>International Journal of Molecular Sciences</i> , 2013, 14, 11171-11189.	1.8	9
778	The Biology of Ewing Sarcoma. <i>ISRN Oncology</i> , 2013, 2013, 1-7.	2.1	54
779	The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. <i>Nucleic Acids Research</i> , 2013, 41, 3688-3698.	6.5	12
780	Design of siRNA Therapeutics from the Molecular Scale. <i>Pharmaceuticals</i> , 2013, 6, 440-468.	1.7	33
781	Prospects for nucleic acid-based therapeutics against hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2013, 19, 8949.	1.4	13
782	siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. <i>Nucleic Acids Research</i> , 2013, 41, e9-e9.	6.5	46
783	The Inhibition of Stat5 by a Peptide Aptamer Ligand Specific for the DNA Binding Domain Prevents Target Gene Transactivation and the Growth of Breast and Prostate Tumor Cells. <i>Pharmaceuticals</i> , 2013, 6, 960-987.	1.7	18
784	Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. <i>Diagnostics</i> , 2013, 3, 170-191.	1.3	22
785	Decrease of Î±-Chains in Î²-Thalassemia. <i>Thalassemia Reports</i> , 2013, 3, e40.	0.1	2
786	Antiviral Stratagems against HIV-1 Using RNA Interference (RNAi) Technology. <i>Evolutionary Bioinformatics</i> , 2013, 9, EBO.S11412.	0.6	20
787	Synthetic microRNA-mediated downregulation of Nogo-A in transgenic rats reveals its role as regulator of synaptic plasticity and cognitive function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6583-6588.	3.3	54
788	Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha ₁ -antitrypsin deficiency. <i>EMBO Molecular Medicine</i> , 2013, 5, 397-412.	3.3	134
789	Studies of Efficacy and Liver Toxicity Related to Adeno-Associated Virus-Mediated RNA Interference. <i>Human Gene Therapy</i> , 2013, 24, 739-750.	1.4	18

#	ARTICLE	IF	CITATIONS
790	Recent advances in α -1-antitrypsin deficiency-related lung disease. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 213-230.	1.0	38
791	Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy. <i>Molecular Therapy</i> , 2013, 21, 217-227.	3.7	22
792	Preclinical In Vivo Evaluation of the Safety of a Multi-shRNA-based Gene Therapy Against HIV-1. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e120.	2.3	42
793	Recent advances in developing nucleic acid-based HBV therapy. <i>Future Microbiology</i> , 2013, 8, 1489-1504.	1.0	6
794	Cytoplasmic RNA viruses as potential vehicles for the delivery of therapeutic small RNAs. <i>Virology Journal</i> , 2013, 10, 185.	1.4	30
795	Inhibition of HBV replication <i>in vivo</i> using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. <i>Antiviral Therapy</i> , 2014, 19, 363-373.	0.6	12
796	Gene Therapy for Hereditary Hearing Loss. <i>Perspectives on Hearing and Hearing Disorders Research and Research Diagnostics</i> , 2013, 17, 5.	0.4	0
797	Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. <i>International Journal of Nanomedicine</i> , 2013, 8, 3907.	3.3	43
798	MicroRNAs may solve the mystery of chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2013, 19, 4867.	1.4	25
799	Approaches to manipulating microRNAs in neurogenesis. <i>Frontiers in Neuroscience</i> , 2012, 6, 196.	1.4	34
802	Lentiviral miR30-based RNA Interference against Heparanase Suppresses Melanoma Metastasis with Lower Liver and Lung Toxicity. <i>International Journal of Biological Sciences</i> , 2013, 9, 564-577.	2.6	27
803	Molecular Characteristics and Efficacy of 16D10 siRNAs in Inhibiting Root-Knot Nematode Infection in Transgenic Grape Hairy Roots. <i>PLoS ONE</i> , 2013, 8, e69463.	1.1	56
804	Systemic Delivery of shRNA by AAV9 Provides Highly Efficient Knockdown of Ubiquitously Expressed GFP in Mouse Heart, but Not Liver. <i>PLoS ONE</i> , 2013, 8, e75894.	1.1	23
805	An RNAi-Based Approach to Down-Regulate a Gene Family In Vivo. <i>PLoS ONE</i> , 2013, 8, e80312.	1.1	2
806	OstemiR: A Novel Panel of MicroRNA Biomarkers in Osteoblastic and Osteocytic Differentiation from Mesenchymal Stem Cells. <i>PLoS ONE</i> , 2013, 8, e58796.	1.1	147
807	Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?. <i>Genes</i> , 2013, 4, 457-484.	1.0	14
808	A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca ²⁺ Uptake into the Sarcoplasmic Reticulum. <i>PLoS ONE</i> , 2014, 9, e92188.	1.1	19
809	Systemic RNAi Delivery to the Muscles of ROSA26 Mice Reduces lacZ Expression. <i>PLoS ONE</i> , 2014, 9, e102053.	1.1	2

#	ARTICLE	IF	CITATIONS
810	Pharmacologic Inhibition of MLK3 Kinase Activity Blocks the In Vitro Migratory Capacity of Breast Cancer Cells but Has No Effect on Breast Cancer Brain Metastasis in a Mouse Xenograft Model. PLoS ONE, 2014, 9, e108487.	1.1	9
811	Influence of Immune Responses in Gene/Stem Cell Therapies for Muscular Dystrophies. BioMed Research International, 2014, 2014, 1-16.	0.9	8
812	Heritable and inducible gene knockdown in astrocytes or neurons in vivo by a combined lentiviral and RNAi approach. Frontiers in Cellular Neuroscience, 2014, 8, 62.	1.8	6
813	Gene therapeutic approaches to inhibit hepatitis B virus replication. World Journal of Hepatology, 2014, 7, 150.	0.8	13
814	Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1121-9.	3.3	134
815	Recombinant AAV as a Platform for Translating the Therapeutic Potential of RNA Interference. Molecular Therapy, 2014, 22, 692-701.	3.7	111
816	Nuclear RNAi Contributes to the Silencing of Off-Target Genes and Repetitive Sequences in <i>Caenorhabditis elegans</i> . Genetics, 2014, 197, 121-132.	1.2	27
817	Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain. Nucleic Acids Research, 2014, 42, 13315-13327.	6.5	17
818	Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Research, 2014, 42, 6787-6810.	6.5	48
819	Optimization of Critical Hairpin Features Allows miRNA-based Gene Knockdown Upon Single-copy Transduction. Molecular Therapy - Nucleic Acids, 2014, 3, e207.	2.3	17
820	Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. Gene Therapy, 2014, 21, 60-70.	2.3	11
821	Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts. European Journal of Human Genetics, 2014, 22, 1369-1375.	1.4	30
822	RNAi-mediated TCR Knockdown Prevents Autoimmunity in Mice Caused by Mixed TCR Dimers Following TCR Gene Transfer. Molecular Therapy, 2014, 22, 1983-1991.	3.7	59
823	Designing Ago2-specific siRNA/shRNA to Avoid Competition with Endogenous miRNAs. Molecular Therapy - Nucleic Acids, 2014, 3, e176.	2.3	34
824	Visible quantum-dot-based targeted siRNA delivery for HIF-1 α gene silencing. Journal of Drug Delivery Science and Technology, 2014, 24, 445-451.	1.4	3
825	Early-Stage Development of Novel Cyclodextrin-siRNA Nanocomplexes Allows for Successful Postnebulization Transfection of Bronchial Epithelial Cells. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2014, 27, 466-477.	0.7	32
826	GHS-R1a signaling in the DMH and VMH contributes to food anticipatory activity. International Journal of Obesity, 2014, 38, 610-618.	1.6	27
827	The Role of MicroRNAs in Diabetic Nephropathy. Journal of Diabetes Research, 2014, 2014, 1-12.	1.0	75

#	ARTICLE	IF	CITATIONS
828	MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics. International Journal of Molecular Sciences, 2014, 15, 10508-10526.	1.8	37
829	Inhibition of Hepatitis B Virus Replication by Helper Dependent Adenoviral Vectors Expressing Artificial Anti-HBV Pri-miRs from a Liver-Specific Promoter. BioMed Research International, 2014, 2014, 1-12.	0.9	25
830	MicroRNAs: Novel Players in Cancer Diagnosis and Therapies. BioMed Research International, 2014, 2014, 1-13.	0.9	57
831	In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma. Molecular Therapy, 2014, 22, 81-91.	3.7	87
832	The MicroRNA Biology of the Mammalian Nucleus. Molecular Therapy - Nucleic Acids, 2014, 3, e188.	2.3	171
833	TALEN-Mediated Somatic Mutagenesis in Murine Models of Cancer. Cancer Research, 2014, 74, 5311-5321.	0.4	26
834	Development of gene therapy for treatment of age-related macular degeneration. Acta Ophthalmologica, 2014, 92, 1-38.	0.6	22
836	An engineered U1 small nuclear RNA rescues splicing-defective coagulation F7 gene expression in mice. Journal of Thrombosis and Haemostasis, 2014, 12, 177-185.	1.9	42
837	RUSH and CRUSH: A rapid and conditional RNA interference method in mice. Genesis, 2014, 52, 39-48.	0.8	2
838	Construction and application of a novel hepatocyte-directed vector to simultaneous knockdown and overexpression of multiple genes. Liver International, 2014, 34, e246-56.	1.9	0
839	Restitution of gene expression and histone acetylation signatures altered by hepatitis B virus through antiviral microRNA-like molecules in nontransformed murine hepatocytes. Clinical Epigenetics, 2014, 6, 26.	1.8	10
840	Weak base pairing in both seed and 3' regions reduces RNAi off-targets and enhances si/shRNA designs. Nucleic Acids Research, 2014, 42, 12169-12176.	6.5	27
841	MicroRNA and Drug Delivery. , 2014, , 359-403.		0
842	Silencing Sexually Transmitted Infections: Topical siRNA-Based Interventions for the Prevention of HIV and HSV. Infectious Diseases in Obstetrics and Gynecology, 2014, 2014, 1-11.	0.4	8
843	microRNAs as a New Mechanism Regulating Adipose Tissue Inflammation in Obesity and as a Novel Therapeutic Strategy in the Metabolic Syndrome. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	74
844	MicroRNAs in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 287-314.	9.6	1,445
845	Generation of stable 3' mRNA cleavage fragments induced by siRNA in cells with high-levels of duck hepatitis B virus replication. Biochemical and Biophysical Research Communications, 2014, 443, 834-839.	1.0	0
846	The application of RNAi-based treatments for inflammatory bowel disease. Drug Delivery and Translational Research, 2014, 4, 4-18.	3.0	12

#	ARTICLE	IF	CITATIONS
847	Biomimetic RNA-silencing Nanocomplexes: Overcoming Multidrug Resistance in Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 1997-2001.	7.2	55
848	Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. <i>Hepatology</i> , 2014, 60, 554-564.	3.6	130
849	A Versatile RNA Vector for Delivery of Coding and Noncoding RNAs. <i>Journal of Virology</i> , 2014, 88, 2333-2336.	1.5	14
852	Polycation-based nanoparticles for RNAi-mediated cancer treatment. <i>Cancer Letters</i> , 2014, 352, 66-80.	3.2	22
853	Long DNA passenger strand highly improves the activity of RNA/DNA hybrid siRNAs. <i>Journal of Bioscience and Bioengineering</i> , 2014, 117, 401-406.	1.1	2
854	Stable RNA interference rules for silencing. <i>Nature Cell Biology</i> , 2014, 16, 10-18.	4.6	153
855	Lentiviral Vector-Mediated RNA Silencing in the Central Nervous System. <i>Human Gene Therapy Methods</i> , 2014, 25, 14-32.	2.1	25
856	Inhibition of BmNPV replication in silkworm cells using inducible and regulated artificial microRNA precursors targeting the essential viral gene lef-11. <i>Antiviral Research</i> , 2014, 104, 143-152.	1.9	48
857	Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. <i>Cancer Gene Therapy</i> , 2014, 21, 48-53.	2.2	17
858	Nucleic Acid Nanotechnology. <i>Nucleic Acids and Molecular Biology</i> , 2014, , .	0.2	5
859	Huntingtin-lowering strategies in Huntington's disease: Antisense oligonucleotides, small RNAs, and gene editing. <i>Movement Disorders</i> , 2014, 29, 1455-1461.	2.2	67
860	Nucleic acid therapeutics: basic concepts and recent developments. <i>RSC Advances</i> , 2014, 4, 16618.	1.7	73
861	A chemical switch for controlling viral infectivity. <i>Chemical Communications</i> , 2014, 50, 10319-10322.	2.2	10
862	Off-Target Effect of doublecortin Family shRNA on Neuronal Migration Associated with Endogenous MicroRNA Dysregulation. <i>Neuron</i> , 2014, 82, 1255-1262.	3.8	79
863	Reconsideration of in silico siRNA design from a perspective of heterogeneous data integration: problems and solutions. <i>Briefings in Bioinformatics</i> , 2014, 15, 292-305.	3.2	8
864	AAV8-Mediated In Vivo Overexpression of miR-155 Enhances the Protective Capacity of Genetically Attenuated Malarial Parasites. <i>Molecular Therapy</i> , 2014, 22, 2130-2141.	3.7	25
865	Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: Prognostic value and prospective role in ovarian cancer therapeutics. <i>Cancer Letters</i> , 2014, 351, 173-181.	3.2	110
866	p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. <i>Cell</i> , 2014, 158, 579-592.	13.5	176

#	ARTICLE	IF	CITATIONS
867	Multifunctional Cationic Lipid-Based Nanoparticles Facilitate Endosomal Escape and Reduction-Triggered Cytosolic siRNA Release. <i>Molecular Pharmaceutics</i> , 2014, 11, 2734-2744.	2.3	145
868	Goat activin receptor type IIB knockdown by muscle specific promoter driven artificial microRNAs. <i>Journal of Biotechnology</i> , 2014, 187, 87-97.	1.9	2
869	Gamma-Retroviral Vector Design for the Co-Expression of Artificial microRNAs and Therapeutic Proteins. <i>Nucleic Acid Therapeutics</i> , 2014, 24, 356-363.	2.0	4
870	shRNA-induced saturation of the microRNA pathway in the rat brain. <i>Gene Therapy</i> , 2014, 21, 205-211.	2.3	31
871	Early lethality of shRNA-transgenic pigs due to saturation of microRNA pathways. <i>Journal of Zhejiang University: Science B</i> , 2014, 15, 466-473.	1.3	11
872	Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy. <i>Biochemical Journal</i> , 2014, 461, 1-13.	1.7	18
873	Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. <i>Methods</i> , 2014, 69, 188-197.	1.9	36
874	<scp>MicroRNAs</scp> as therapeutic targets in human cancers. <i>Wiley Interdisciplinary Reviews RNA</i> , 2014, 5, 537-548.	3.2	80
875	siRNA: novel therapeutics from functional genomics. <i>Biotechnology and Genetic Engineering Reviews</i> , 2014, 30, 1-30.	2.4	11
876	CRISPR/Cas9-mediated genome engineering: An adeno-associated viral (AAV) vector toolbox. <i>Biotechnology Journal</i> , 2014, 9, 1402-1412.	1.8	235
877	Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects. <i>Brain Research</i> , 2014, 1550, 47-60.	1.1	45
878	A 21st-century approach to age-old problems: the ascension of biologics in clinical therapeutics. <i>Drug Discovery Today</i> , 2014, 19, 1109-1113.	3.2	27
879	Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 1481-1495.	2.4	22
880	Significant inhibition of two different genotypes of grass carp reovirus in vitro using multiple shRNAs expression vectors. <i>Virus Research</i> , 2014, 189, 47-55.	1.1	14
881	New insight into the RNA interference response against cathepsin-L gene in the pea aphid, <i>Acyrtosiphon pisum</i> : Molting or gut phenotypes specifically induced by injection or feeding treatments. <i>Insect Biochemistry and Molecular Biology</i> , 2014, 51, 20-32.	1.2	75
882	Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 1-20.	2.4	24
883	The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30. <i>Frontiers in Genetics</i> , 2014, 4, 301.	1.1	27
884	A simplified purification protocol for recombinant adeno-associated virus vectors. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14034.	1.8	56

#	ARTICLE	IF	CITATIONS
885	Validated MicroRNA Target Databases: An Evaluation. Drug Development Research, 2015, 76, 389-396.	1.4	50
886	<i>Alu</i> element-containing <i>RNA</i> s maintain nucleolar structure and function. EMBO Journal, 2015, 34, 2758-2774.	3.5	118
887	Combinatorial RNA Interference Therapy Prevents Selection of Pre-existing HBV Variants in Human Liver Chimeric Mice. Scientific Reports, 2015, 5, 15259.	1.6	16
888	Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14064.	1.8	43
889	MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomarker Insights, 2015, 10s4, BMI.S29512.	1.0	26
890	Antiviral Phosphorodiamidate Morpholino Oligomers are Protective against Chikungunya Virus Infection on Cell-based and Murine Models. Scientific Reports, 2015, 5, 12727.	1.6	13
891	A large-scale functional screen identifies <i>N</i> ova1 and <i>N</i> coa3 as regulators of neuronal mi <i>RNA</i> function. EMBO Journal, 2015, 34, 2237-2254.	3.5	44
892	Effective small interfering RNA delivery in vitro via a new stearylated cationic peptide. International Journal of Nanomedicine, 2015, 10, 3303.	3.3	15
893	RNA as a Therapeutic Molecule. , 2015, , 769-778.e2.		1
894	“Skeletal Muscle MicroRNAs: Their Diagnostic and Therapeutic Potential in Human Muscle Diseases” Journal of Neuromuscular Diseases, 2015, 2, 1-11.	1.1	35
895	Progress and Prospects of Anti-HBV Gene Therapy Development. International Journal of Molecular Sciences, 2015, 16, 17589-17610.	1.8	31
896	Innovative Delivery of siRNA to Solid Tumors by Super Carbonate Apatite. PLoS ONE, 2015, 10, e0116022.	1.1	29
898	Artificial MiRNA Knockdown of Platelet Glycoprotein Ib: A Tool for Platelet Gene Silencing. PLoS ONE, 2015, 10, e0132899.	1.1	0
899	Assessment of Artificial MiRNA Architectures for Higher Knockdown Efficiencies without the Undesired Effects in Mice. PLoS ONE, 2015, 10, e0135919.	1.1	6
900	Hepatitis B Virus Infection, MicroRNAs and Liver Disease. International Journal of Molecular Sciences, 2015, 16, 17746-17762.	1.8	42
901	Adeno-Associated Virus-Mediated MicroRNA Delivery and Therapeutics. Seminars in Liver Disease, 2015, 35, 081-088.	1.8	30
902	Harnessing RNAi to Silence Viral Gene Expression. , 2015, , 29-61.		1
903	Gene Therapy for Hepatitis C Virus Infection. , 2015, , 191-226.		0

#	ARTICLE	IF	CITATIONS
904	Gene Therapy for Chronic Hepatitis B Virus Infection. , 2015, , 151-189.		0
905	Antiviral Gene Therapy. , 2015, , 355-364.		2
907	Recombinase-based conditional and reversible gene regulation via XTR alleles. Nature Communications, 2015, 6, 8783.	5.8	31
908	microRNAs and Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2015, 888, 85-105.	0.8	84
909	Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nature Reviews Drug Discovery, 2015, 14, 843-856.	21.5	349
910	Potential of antisense therapy for facioscapulohumeral muscular dystrophy. Expert Opinion on Orphan Drugs, 2015, 3, 1365-1374.	0.5	2
911	Double transduction of a Cre/LoxP lentiviral vector: a simple method to generate kidney cell-specific knockdown mice. American Journal of Physiology - Renal Physiology, 2015, 309, F1060-F1069.	1.3	11
912	CRISPR genome engineering and viral gene delivery: A case of mutual attraction. Biotechnology Journal, 2015, 10, 258-272.	1.8	73
913	Effects of transgenic sterilization constructs and their repressor compounds on hatch, developmental rate and early survival of electroporated channel catfish embryos and fry. Transgenic Research, 2015, 24, 333-352.	1.3	5
914	Delivering a disease-modifying treatment for Huntington's disease. Drug Discovery Today, 2015, 20, 50-64.	3.2	39
915	Advances, Nuances, and Potential Pitfalls When Exploiting the Therapeutic Potential of RNA Interference. Clinical Pharmacology and Therapeutics, 2015, 97, 79-87.	2.3	13
916	RNA-Based Therapies for Bone Diseases. , 2015, , 1049-1073.		1
917	Long chain microRNA conjugates in calcium phosphate nanoparticles for efficient formulation and delivery. Archives of Pharmacal Research, 2015, 38, 705-715.	2.7	20
918	Drugging RNAi. Science, 2015, 347, 1069-1070.	6.0	74
919	Genome Engineering for Therapeutic Applications. , 2015, , 27-43.		4
920	Next-generation libraries for robust RNA interference-based genome-wide screens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3384-91.	3.3	83
921	Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4007-16.	3.3	33
922	Aurora Kinase B Regulates Telomerase Activity via a Centromeric RNA in Stem Cells. Cell Reports, 2015, 11, 1667-1678.	2.9	31

#	ARTICLE	IF	CITATIONS
923	The intracellular pharmacodynamics of siRNA is responsible for the low gene silencing activity of siRNA-loaded nanoparticles in dendritic cells. <i>International Journal of Pharmaceutics</i> , 2015, 494, 271-277.	2.6	7
924	CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. <i>Brain</i> , 2015, 138, 2383-2398.	3.7	163
925	Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. <i>Frontiers in Oncology</i> , 2015, 5, 5.	1.3	203
926	Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. <i>Human Molecular Genetics</i> , 2015, 24, 4971-4983.	1.4	43
927	miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. <i>Molecular Therapy</i> , 2015, 23, 1465-1474.	3.7	101
928	In vivo RNAi screens: concepts and applications. <i>Trends in Immunology</i> , 2015, 36, 315-322.	2.9	18
929	RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies. <i>Molecular BioSystems</i> , 2015, 11, 2635-2657.	2.9	7
930	Gene therapy to treat cardiac arrhythmias. <i>Nature Reviews Cardiology</i> , 2015, 12, 531-546.	6.1	42
931	Autoregulation of Inducible Nitric Oxide Synthase Expression by RNA Interference Provides Neuroprotection in Neonatal Rats. <i>Theranostics</i> , 2015, 5, 504-514.	4.6	16
932	Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. <i>Journal of Virology</i> , 2015, 89, 6761-6772.	1.5	30
933	Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Cocksackievirus B3-induced Myocarditis in Mice. <i>Journal of Infectious Diseases</i> , 2015, 211, 613-622.	1.9	17
934	Fighting against kidney diseases with small interfering RNA: opportunities and challenges. <i>Journal of Translational Medicine</i> , 2015, 13, 39.	1.8	20
935	Synergistic inhibition of avian leukosis virus subgroup J replication by miRNA-embedded siRNA interference of double-target. <i>Virology Journal</i> , 2015, 12, 45.	1.4	7
936	siRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery. <i>Ageing Research Reviews</i> , 2015, 21, 43-54.	5.0	45
937	Recent Advances in Use of Gene Therapy to Treat Hepatitis B Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 31-49.	0.8	4
938	Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. <i>Nucleic Acids Research</i> , 2015, 43, 3407-3419.	6.5	124
940	U1 interference (U1i) for Antiviral Approaches. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 51-69.	0.8	10
941	Gene Therapy Strategies to Block HIV-1 Replication by RNA Interference. <i>Advances in Experimental Medicine and Biology</i> , 2015, 848, 71-95.	0.8	12

#	ARTICLE	IF	CITATIONS
942	Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy. <i>Human Gene Therapy</i> , 2015, 26, 709-718.	1.4	17
943	RALA-mediated delivery of FKBPL nucleic acid therapeutics. <i>Nanomedicine</i> , 2015, 10, 2989-3001.	1.7	57
944	Viral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioning. <i>Neurobiology of Learning and Memory</i> , 2015, 124, 34-47.	1.0	8
945	siRNA Versus miRNA as Therapeutics for Gene Silencing. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e252.	2.3	730
946	Transgenerational epigenetic programming via sperm microRNA recapitulates effects of paternal stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13699-13704.	3.3	590
947	Ribozyme-enhanced single-stranded Ago2-processed interfering RNA triggers efficient gene silencing with fewer off-target effects. <i>Nature Communications</i> , 2015, 6, 8430.	5.8	24
948	The regulatory roles of non-coding RNAs in nerve injury and regeneration. <i>Progress in Neurobiology</i> , 2015, 134, 122-139.	2.8	85
949	Controlling mRNA stability and translation with the CRISPR endoribonuclease Csy4. <i>Rna</i> , 2015, 21, 1921-1930.	1.6	23
950	microRNAs: Modulators of the underlying pathophysiology of sarcopenia?. <i>Ageing Research Reviews</i> , 2015, 24, 263-273.	5.0	62
951	Use of a three-dimensional humanized liver model for the study of viral gene vectors. <i>Journal of Biotechnology</i> , 2015, 212, 134-143.	1.9	7
952	Minicircle DNA vectors for gene therapy: advances and applications. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 353-379.	1.4	73
953	Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. <i>Gene Therapy</i> , 2015, 22, 163-171.	2.3	27
954	Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. <i>Advanced Drug Delivery Reviews</i> , 2015, 81, 142-160.	6.6	208
955	Potential mechanisms for cell-based gene therapy to treat HIV/AIDS. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 245-263.	1.5	13
957	Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. <i>Nature</i> , 2015, 517, 360-364.	13.7	226
958	Multiplexing Seven miRNA-Based shRNAs to Suppress HIV Replication. <i>Molecular Therapy</i> , 2015, 23, 310-320.	3.7	32
959	RNA Interference – A Hallmark of Cellular Function and Gene Manipulation. , 0, , .		3
960	RNAi Therapeutic Potentials and Prospects in CNS Disease. , 0, , .		1

#	ARTICLE	IF	CITATIONS
961	RNAi Efficiency, Systemic Properties, and Novel Delivery Methods for Pest Insect Control: What We Know So Far. <i>Frontiers in Physiology</i> , 2016, 7, 553.	1.3	386
962	Small RNA Delivery for In Situ Tissue Regeneration. , 2016, , 111-135.		2
963	siRNA-Induced RNAi Therapy in Acute Kidney Injury. , 0, , .		0
964	Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy. <i>Intractable and Rare Diseases Research</i> , 2016, 5, 168-176.	0.3	7
965	Gene, Stem Cell, and Alternative Therapies for SCA 1. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 67.	1.4	12
966	The Development of a Viral Mediated CRISPR/Cas9 System with Doxycycline Dependent gRNA Expression for Inducible In vitro and In vivo Genome Editing. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 70.	1.4	50
967	Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 424.	1.8	96
968	MiRNA-Embedded ShRNAs for Radiation-Inducible LGMN Knockdown and the Antitumor Effects on Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0163446.	1.1	5
969	Off Target, but Sequence-Specific, shRNA-Associated Trans-Activation of Promoter Reporters in Transient Transfection Assays. <i>PLoS ONE</i> , 2016, 11, e0167867.	1.1	1
970	MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers. <i>Frontiers in Pharmacology</i> , 2016, 7, 329.	1.6	34
971	Stacking up <sc>CRISPR</sc> against <sc>RNA</sc>i for therapeutic gene inhibition. <i>FEBS Journal</i> , 2016, 283, 3249-3260.	2.2	15
972	Biological antivirals for treatment of adenovirus infections. <i>Antiviral Therapy</i> , 2016, 21, 559-566.	0.6	13
973	Chemical Vapor Deposition (CVD). , 2016, , 518-524.		0
974	Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development. <i>Molecular Pain</i> , 2016, 12, 174480691665396.	1.0	13
975	Small RNAs/Cancer. , 2016, , 364-374.		0
976	Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?. <i>Journal of Huntington's Disease</i> , 2016, 5, 33-38.	0.9	5
977	Chitosan. , 2016, , 524-524.		0
978	The miR-125 family is an important regulator of the expression and maintenance of maternal effect genes during preimplantational embryo development. <i>Open Biology</i> , 2016, 6, 160181.	1.5	34

#	ARTICLE	IF	CITATIONS
979	Noncoding RNA for Cancer Gene Therapy. Recent Results in Cancer Research, 2016, 209, 51-60.	1.8	15
980	Successful disabling of the 5' UTR of HCV using adeno-associated viral vectors to deliver modular multimeric primary microRNA mimics. Journal of Virological Methods, 2016, 235, 26-33.	1.0	6
981	RNA interference-induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice. Nature Medicine, 2016, 22, 557-562.	15.2	32
982	Guidelines for the optimal design of miRNA-based shRNAs. Methods, 2016, 103, 157-166.	1.9	63
983	Smooth Muscle Enriched Long Noncoding RNA (<i>SMILR</i>) Regulates Cell Proliferation. Circulation, 2016, 133, 2050-2065.	1.6	182
984	Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nature Biotechnology, 2016, 34, 634-636.	9.4	359
985	Adenoviral Vectors for RNAi Delivery. , 2016, , 739-765.		0
986	A Guide to Genome-Wide In Vivo RNAi Applications in Drosophila. Methods in Molecular Biology, 2016, 1478, 117-143.	0.4	32
987	Tailored Nanoparticle Codelivery of antimir-21 and antimir-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a Personalized Anti-microRNA Therapy. Molecular Pharmaceutics, 2016, 13, 3164-3175.	2.3	43
988	Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents. Cell Metabolism, 2016, 24, 234-245.	7.2	103
989	mRNA trans-splicing in gene therapy for genetic diseases. Wiley Interdisciplinary Reviews RNA, 2016, 7, 487-498.	3.2	61
990	MicroRNAs in heart failure: from biomarker to target for therapy. European Journal of Heart Failure, 2016, 18, 457-468.	2.9	235
991	Targeted disruption of influenza A virus hemagglutinin in genetically modified mice reduces viral replication and improves disease outcome. Scientific Reports, 2016, 6, 23746.	1.6	12
992	Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. Journal of Controlled Release, 2016, 241, 94-109.	4.8	148
993	RNA interference of a trehalose-6-phosphate synthase gene reveals its roles during larval-pupal metamorphosis in Bactrocera minax (Diptera: Tephritidae). Journal of Insect Physiology, 2016, 91-92, 84-92.	0.9	56
994	Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia. Molecular Therapy - Nucleic Acids, 2016, 5, e383.	2.3	11
995	A universal system to select gene-modified hepatocytes in vivo. Science Translational Medicine, 2016, 8, 342ra79.	5.8	38
996	Inhibition of miR-21 in glioma cells using catalytic nucleic acids. Scientific Reports, 2016, 6, 24516.	1.6	33

#	ARTICLE	IF	CITATIONS
997	Attacking HIV-1 RNA versus DNA by sequence-specific approaches: RNAi versus CRISPR-Cas. <i>Biochemical Society Transactions</i> , 2016, 44, 1355-1365.	1.6	20
998	Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. <i>EMBO Molecular Medicine</i> , 2016, 8, 1082-1098.	3.3	24
999	<i>Plasmodium</i> meets AAV—the (un)likely marriage of parasitology and virology, and how to make the match. <i>FEBS Letters</i> , 2016, 590, 2027-2045.	1.3	1
1000	Construction of Modular Lentiviral Vectors for Effective Gene Expression and Knockdown. <i>Methods in Molecular Biology</i> , 2016, 1448, 3-21.	0.4	5
1001	Efficient inhibition of human immunodeficiency virus replication using novel modified microRNA-30a targeting 3'-untranslated region transcripts. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 1833-1838.	0.8	3
1002	Inhibiting avian influenza virus shedding using a novel RNAi antiviral vector technology: proof of concept in an avian cell model. <i>AMB Express</i> , 2016, 6, 16.	1.4	6
1003	Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1 ^{G93A} Mice and Nonhuman Primates. <i>Human Gene Therapy</i> , 2016, 27, 19-31.	1.4	85
1004	Advanced Design of Dumbbell-shaped Genetic Minimal Vectors Improves Non-coding and Coding RNA Expression. <i>Molecular Therapy</i> , 2016, 24, 1581-1591.	3.7	12
1005	Folic Acid-Mediated Functionalized Gold Nanocages for Targeted Delivery of Anti-miR-181b in Combination of Gene Therapy and Photothermal Therapy against Hepatocellular Carcinoma. <i>Advanced Functional Materials</i> , 2016, 26, 2532-2544.	7.8	111
1006	Inducible RNAi system and its application in novel therapeutics. <i>Critical Reviews in Biotechnology</i> , 2016, 36, 630-638.	5.1	15
1007	Quantitative evaluation of first, second, and third generation hairpin systems reveals the limit of mammalian vector-based RNAi. <i>RNA Biology</i> , 2016, 13, 25-33.	1.5	27
1008	Editing the epigenome: technologies for programmable transcription and epigenetic modulation. <i>Nature Methods</i> , 2016, 13, 127-137.	9.0	341
1009	Improved knockdown from artificial microRNAs in an enhanced miR-155 backbone: a designer's guide to potent multi-target RNAi. <i>Nucleic Acids Research</i> , 2016, 44, e48-e48.	6.5	22
1010	Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e278.	2.3	6
1011	A multiplexed miRNA and transgene expression platform for simultaneous repression and expression of protein coding sequences. <i>Molecular BioSystems</i> , 2016, 12, 295-312.	2.9	17
1012	Sequence-non-specific effects generated by various types of RNA interference triggers. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 306-314.	0.9	19
1013	Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 174-186.	6.6	38
1014	Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e297.	2.3	97

#	ARTICLE	IF	CITATIONS
1015	From Loci to Biology. <i>Circulation Research</i> , 2016, 118, 586-606.	2.0	54
1016	Cardiac <i>Stim1</i> Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling. <i>Circulation</i> , 2016, 133, 1458-1471.	1.6	84
1017	A new plasmid-based microRNA inhibitor system that inhibits microRNA families in transgenic mice and cells: a potential new therapeutic reagent. <i>Gene Therapy</i> , 2016, 23, 527-542.	2.3	32
1018	Dietary Indoles Suppress Delayed-Type Hypersensitivity by Inducing a Switch from Proinflammatory Th17 Cells to Anti-Inflammatory Regulatory T Cells through Regulation of MicroRNA. <i>Journal of Immunology</i> , 2016, 196, 1108-1122.	0.4	105
1019	Introduction to Viral Vectors and Other Delivery Methods for Gene Therapy of the Nervous System. <i>Methods in Molecular Biology</i> , 2016, 1382, 3-18.	0.4	7
1020	Synthetic SiRNA Delivery: Progress and Prospects. <i>Methods in Molecular Biology</i> , 2016, 1364, 291-310.	0.4	39
1021	Efficient Gene Suppression in Dorsal Root Ganglia and Spinal Cord Using Adeno-Associated Virus Vectors Encoding Short-Hairpin RNA. <i>Methods in Molecular Biology</i> , 2016, 1364, 277-290.	0.4	4
1022	Viral vectors for therapy of neurologic diseases. <i>Neuropharmacology</i> , 2017, 120, 63-80.	2.0	130
1023	Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 221-232.	2.3	12
1024	RNA interference-based technology: what role in animal agriculture?. <i>Animal Production Science</i> , 2017, 57, 1.	0.6	11
1025	<i>Plasmodium berghei</i> EXP-1 interacts with host Apolipoprotein H during <i>Plasmodium</i> liver-stage development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E1138-E1147.	3.3	43
1026	Exploiting microRNAs As Cancer Therapeutics. <i>Targeted Oncology</i> , 2017, 12, 163-178.	1.7	18
1027	miR-92a enhances recombinant protein productivity in CHO cells by increasing intracellular cholesterol levels. <i>Biotechnology Journal</i> , 2017, 12, 1600488.	1.8	26
1028	Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond. <i>Human Gene Therapy</i> , 2017, 28, 361-372.	1.4	40
1029	Lentiviral vector-encoded microRNA-based shRNA-mediated gene knockdown of <i>N-methyl-D-aspartate</i> receptors in skin reduces pain. <i>Brain and Behavior</i> , 2017, 7, e00587.	1.0	8
1030	Worth the RISC?. <i>Nature Biotechnology</i> , 2017, 35, 198-202.	9.4	24
1031	The Influence of Extracellular RNA on Cell Behavior in Health, Disease, and Regeneration. <i>Current Pathobiology Reports</i> , 2017, 5, 13-22.	1.6	6
1032	Prediction of potent shRNAs with a sequential classification algorithm. <i>Nature Biotechnology</i> , 2017, 35, 350-353.	9.4	129

#	ARTICLE	IF	CITATIONS
1033	Caspase-3 and GFAP as early markers for apoptosis and astrogliosis in shRNA-induced hippocampal cytotoxicity. <i>Journal of Experimental Biology</i> , 2017, 220, 1400-1404.	0.8	11
1034	Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 7, 190-199.	2.3	20
1035	Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. <i>Nature Communications</i> , 2017, 8, 15178.	5.8	284
1036	Long-term regulation of gene expression in muscle cells by systemically delivered siRNA. <i>Journal of Controlled Release</i> , 2017, 256, 101-113.	4.8	6
1037	RNAi-mediated knockdown of mouse melanocortin-4 receptor <i>in vitro</i> and <i>in vivo</i> , using an siRNA expression construct based on the mir-187 precursor. <i>Experimental Animals</i> , 2017, 66, 41-50.	0.7	0
1038	Safe and Efficient Silencing with a Pol II, but Not a Pol III, Promoter Expressing an Artificial miRNA Targeting Human Huntingtin. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 7, 324-334.	2.3	25
1039	Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF- β 2 in HBV-persistent mice. <i>Scientific Reports</i> , 2017, 7, 3860.	1.6	8
1040	An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries. <i>Biomaterials</i> , 2017, 139, 102-115.	5.7	24
1041	Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 5, 259-276.	1.8	13
1042	Polymers in the Delivery of siRNA for the Treatment of Virus Infections. <i>Topics in Current Chemistry</i> , 2017, 375, 38.	3.0	12
1043	Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6461-6479.	2.9	72
1044	Composite vector formulation for multiple siRNA delivery as a host targeting antiviral in a cell culture model of hepatitis C virus (HCV) infection. <i>Journal of Materials Chemistry B</i> , 2017, 5, 858-865.	2.9	4
1045	Expression of short hairpin RNAs using the compact architecture of retroviral microRNA genes. <i>Nucleic Acids Research</i> , 2017, 45, e154-e154.	6.5	5
1046	Suppression of Choroidal Neovascularization in Mice by Subretinal Delivery of Multigenic Lentiviral Vectors Encoding Anti-Angiogenic MicroRNAs. <i>Human Gene Therapy Methods</i> , 2017, 28, 222-233.	2.1	20
1047	The use of nanoparticulates to treat breast cancer. <i>Nanomedicine</i> , 2017, 12, 2367-2388.	1.7	74
1048	Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors. <i>Human Gene Therapy Methods</i> , 2017, 28, 177-190.	2.1	52
1049	Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 300-316.	2.3	18
1050	MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 345-365.	1.3	81

#	ARTICLE	IF	CITATIONS
1051	Suppression of choroidal neovascularization in mice by subretinal delivery of multigenic lentiviral vectors encoding anti-angiogenic microRNAs. <i>Human Gene Therapy Methods</i> , 2017, , .	2.1	1
1052	Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
1053	MicroRNA-mediated disruption of dendritogenesis during a critical period of development influences cognitive capacity later in life. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 9188-9193.	3.3	23
1054	Literature review of baseline information to support the risk assessment of RNAi-based GM plants. <i>EFSA Supporting Publications</i> , 2017, 14, 1246E.	0.3	15
1055	A microRNA screen reveals that elevated hepatic ectodysplasin A expression contributes to obesity-induced insulin resistance in skeletal muscle. <i>Nature Medicine</i> , 2017, 23, 1466-1473.	15.2	51
1056	Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes <i>egfr1</i> and <i>erbb2</i> to regress mouse breast tumor. <i>Drug Delivery</i> , 2017, 24, 1721-1730.	2.5	22
1057	The state of gene therapy research in Africa, its significance and implications for the future. <i>Gene Therapy</i> , 2017, 24, 581-589.	2.3	11
1058	Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. <i>Nature Reviews Genetics</i> , 2017, 18, 24-40.	7.7	159
1059	<i>In Vitro</i> Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells. <i>Nucleic Acid Therapeutics</i> , 2017, 27, 45-55.	2.0	26
1060	CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues. <i>Arthritis and Rheumatology</i> , 2017, 69, 1111-1121.	2.9	61
1061	MicroRNAs and Cancer. , 2017, , 277-286.		11
1062	Targeting GH-1 splicing as a novel pharmacological strategy for growth hormone deficiency type II. <i>Biochemical Pharmacology</i> , 2017, 124, 1-9.	2.0	2
1063	Silencing strategies for therapy of SOD1-mediated ALS. <i>Neuroscience Letters</i> , 2017, 636, 32-39.	1.0	55
1064	Liposome-based drug co-delivery systems in cancer cells. <i>Materials Science and Engineering C</i> , 2017, 71, 1327-1341.	3.8	242
1065	TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus. <i>Nucleic Acids Research</i> , 2017, 45, e3-e3.	6.5	8
1066	RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA. <i>Translational Neurodegeneration</i> , 2017, 6, 30.	3.6	47
1067	Increased Neutralizing Antibody Production and Interferon- β Secretion in Response to Porcine Reproductive and Respiratory Syndrome Virus Immunization in Genetically Modified Pigs. <i>Frontiers in Immunology</i> , 2017, 8, 1110.	2.2	10
1068	Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism. <i>ELife</i> , 2017, 6, .	2.8	62

#	ARTICLE	IF	CITATIONS
1069	4.33 Engineering Viruses For Gene Therapy. , 2017, , 600-616.		0
1070	Gene suppression approaches to neurodegeneration. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 82.	3.0	46
1071	Multiple genes contribute to anhydrobiosis (tolerance to extreme desiccation) in the nematode <i>Panagrolaimus superbus</i> . <i>Genetics and Molecular Biology</i> , 2017, 40, 790-802.	0.6	11
1072	Risk associated with off-target plant genome editing and methods for its limitation. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 231-240.	1.1	56
1073	Current Progress and Future Prospects in Nucleic Acid Based Therapeutics. , 2017, , 280-313.		4
1074	Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. <i>Nature Communications</i> , 2018, 9, 723.	5.8	173
1075	Therapeutic applications of group I intronâ€based <i>trans</i>-splicing ribozymes. <i>Wiley Interdisciplinary Reviews RNA</i> , 2018, 9, e1466.	3.2	16
1076	Single Intramuscular Injection of AAV-shRNA Reduces DNMT2 and Prevents Myotubular Myopathy in Mice. <i>Molecular Therapy</i> , 2018, 26, 1082-1092.	3.7	35
1077	MicroRNA Protocols. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	4
1078	Mechanism and Method for Generating Tumor-Free iPS Cells Using Intronic MicroRNA miR-302 Induction. <i>Methods in Molecular Biology</i> , 2018, 1733, 265-282.	0.4	11
1079	Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 8, 121-130.	1.8	44
1080	Selective α -Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinsonâ€™s Disease. <i>Molecular Therapy</i> , 2018, 26, 550-567.	3.7	97
1081	How successful has targeted RNA interference for hepatic fibrosis been?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 381-388.	1.4	2
1082	Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. <i>Nucleic Acids Research</i> , 2018, 46, 1584-1600.	6.5	487
1083	Aptamer-Based Control of Gene Expression Utilizing Endogenous miRNAs. <i>Molecular Therapy</i> , 2018, 26, 1178-1180.	3.7	1
1084	Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Donâ€™t. <i>Nucleic Acid Therapeutics</i> , 2018, 28, 166-177.	2.0	94
1085	Off and back-on again: a tumor suppressorâ€™s tale. <i>Oncogene</i> , 2018, 37, 3058-3069.	2.6	12
1086	Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells. <i>Nucleic Acids Research</i> , 2018, 46, 4456-4468.	6.5	63

#	ARTICLE	IF	CITATIONS
1087	Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic. <i>Molecular Therapy</i> , 2018, 26, 947-962.	3.7	29
1088	Conditional Manipulation of Gene Function in Human Cells with Optimized Inducible shRNA. <i>Current Protocols in Stem Cell Biology</i> , 2018, 44, 5C.4.1-5C.4.48.	3.0	11
1089	Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. <i>European Heart Journal</i> , 2018, 39, 2704-2716.	1.0	300
1090	Dissecting microRNA dysregulation in age-related macular degeneration: new targets for eye gene therapy. <i>Acta Ophthalmologica</i> , 2018, 96, 9-23.	0.6	37
1091	Dual MicroRNA to Cellular Prion Protein Inhibits Propagation of Pathogenic Prion Protein in Cultured Cells. <i>Molecular Neurobiology</i> , 2018, 55, 2384-2396.	1.9	9
1092	MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 224-233.	2.9	27
1093	Stress-induced changes in miRNA biogenesis and functioning. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 177-191.	2.4	123
1094	Gene Therapy to Treat Cardiac Arrhythmias. , 2018, , 531-540.		1
1095	Inducing indel mutation in the <i>SOX6</i> gene by zinc finger nuclease for gamma reactivation: An approach towards gene therapy of beta thalassemia. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 2512-2519.	1.2	16
1096	Therapy development in Huntington disease: From current strategies to emerging opportunities. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 842-861.	0.7	75
1097	Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. <i>Glia</i> , 2018, 66, 413-427.	2.5	55
1098	Molecular Biology in Tardigrades. <i>Zoological Monographs</i> , 2018, , 331-347.	1.1	2
1099	Water Bears: The Biology of Tardigrades. <i>Zoological Monographs</i> , 2018, , .	1.1	24
1100	siRNA: A Promising New Tool for Future Breast Cancer Therapy. <i>Oncomedicine</i> , 2018, 3, 74-81.	1.1	7
1101	miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression. <i>Nature Communications</i> , 2018, 9, 5321.	5.8	48
1102	Expression of Duplex shRNAs through a Lentiviral Vector against Cellular and Viral Genes Inflicts Sustained Inhibition of Hepatitis C Virus Replication. <i>Intervirology</i> , 2018, 61, 79-91.	1.2	1
1103	RNA interference to enhance radiation therapy: Targeting the DNA damage response. <i>Cancer Letters</i> , 2018, 439, 14-23.	3.2	9
1104	Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges. <i>Frontiers in Pharmacology</i> , 2018, 9, 1090.	1.6	21

#	ARTICLE	IF	CITATIONS
1105	The therapeutic potential of RNA regulation in neurological disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 1017-1028.	1.5	17
1106	The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons in vivo and Regulated via Doxycycline and Cre-Recombinase. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 413.	1.4	56
1107	Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	59
1108	Group I Intron-Based Therapeutics Through Trans-Splicing Reaction. <i>Progress in Molecular Biology and Translational Science</i> , 2018, 159, 79-100.	0.9	2
1109	The neuronal migration hypothesis of dyslexia: A critical evaluation 30 years on. <i>European Journal of Neuroscience</i> , 2018, 48, 3212-3233.	1.2	48
1110	Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β^2 -Thalassemia Major. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 10, 313-326.	1.8	83
1111	Specific Targeting of Oncogenes Using CRISPR Technology. <i>Cancer Research</i> , 2018, 78, 5506-5512.	0.4	6
1112	A triumph of perseverance over interference. <i>Nature Biotechnology</i> , 2018, 36, 775-775.	9.4	9
1113	CK1 α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. <i>Blood</i> , 2018, 132, 577-586.	0.6	39
1114	Biomolecular Therapeutics for HIV. , 2018, , 541-567.		2
1115	DROSHA Knockout Leads to Enhancement of Viral Titers for Vectors Encoding miRNA-Adapted shRNAs. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 12, 591-599.	2.3	5
1116	Current Strategies for Inhibition of Chikungunya Infection. <i>Viruses</i> , 2018, 10, 235.	1.5	72
1117	Small RNA-mediated prevention, diagnosis and therapies of cancer. , 2018, , 341-436.		0
1118	miRNAs in Tuberculosis: New Avenues for Diagnosis and Host-Directed Therapy. <i>Frontiers in Microbiology</i> , 2018, 9, 602.	1.5	73
1119	Transduction with Lentiviral Vectors Altered the Expression Profile of Host MicroRNAs. <i>Journal of Virology</i> , 2018, 92, .	1.5	16
1120	RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis. <i>Biomedicines</i> , 2018, 6, 9.	1.4	20
1121	Optimization of Polycistronic Anti-CCR5 Artificial microRNA Leads to Improved Accuracy of Its Lentiviral Vector Transfer and More Potent Inhibition of HIV-1 in CD4+ T-Cells. <i>Cells</i> , 2018, 7, 10.	1.8	7
1122	Gene Therapy for Chronic HBV – Can We Eliminate cccDNA?. <i>Genes</i> , 2018, 9, 207.	1.0	52

#	ARTICLE	IF	CITATIONS
1123	AAV vector-mediated in vivo reprogramming into pluripotency. <i>Nature Communications</i> , 2018, 9, 2651.	5.8	43
1124	Disruption of <i>SOX6</i> gene using CRISPR/Cas9 technology for gamma-globin reactivation: An approach towards gene therapy of β^0 -thalassemia. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 9357-9363.	1.2	29
1125	Theranostic Magnetic Nanoparticles as Molecular Imaging Agents for siRNA Delivery. , 2018, , 551-576.		1
1126	State of art and limitations in genetic engineering to induce stable chondrogenic phenotype. <i>Biotechnology Advances</i> , 2018, 36, 1855-1869.	6.0	15
1127	Nonspecific inhibition of erythropoiesis by short hairpin RNAs. <i>Blood</i> , 2018, 131, 2733-2736.	0.6	9
1128	Literature review of baseline information on RNAi to support the environmental risk assessment of RNAi-based GM plants. <i>EFSA Supporting Publications</i> , 2018, 15, 1424E.	0.3	63
1129	Evidence for the Involvement of the Master Transcription Factor NF- κ B in Cancer Initiation and Progression. <i>Biomedicines</i> , 2018, 6, 82.	1.4	161
1130	Targeting Transgene and RNA Interference-Based Gene Silencing Sequences to Astrocytes Using Viral Vector-Mediated Approaches. , 2018, , 41-61.		0
1131	Strategies for improving the specificity of siRNAs for enhanced therapeutic potential. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 709-725.	2.5	10
1132	Artificial MicroRNA-Mediated <i>Tgfr2</i> and <i>Pdgfrb</i> Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice. <i>Human Gene Therapy</i> , 2019, 30, 179-196.	1.4	13
1133	Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 1101-1110.	0.9	10
1134	Modulation of the dual-faced effects of miR-141 with chitosan/miR-141 nanoplexes in breast cancer cells. <i>Journal of Gene Medicine</i> , 2019, 21, e3116.	1.4	11
1135	Gene Therapy Tools for Brain Diseases. <i>Frontiers in Pharmacology</i> , 2019, 10, 724.	1.6	131
1136	Next-generation AAV vectors "do not judge a virus (only) by its cover. <i>Human Molecular Genetics</i> , 2019, 28, R3-R14.	1.4	105
1137	Bone-targeting AAV-mediated silencing of <i>Schnurri-3</i> prevents bone loss in osteoporosis. <i>Nature Communications</i> , 2019, 10, 2958.	5.8	70
1138	RNA therapies explained. <i>Nature</i> , 2019, 574, S2-S3.	13.7	29
1139	AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 275-284.	1.8	38
1140	Gene knockdown in malaria parasites via non-canonical RNAi. <i>Nucleic Acids Research</i> , 2020, 48, e2.	6.5	10

#	ARTICLE	IF	CITATIONS
1141	FOXN3 controls liver glucose metabolism by regulating gluconeogenic substrate selection. <i>Physiological Reports</i> , 2019, 7, e14238.	0.7	6
1142	RNAi as a tool to inhibit the angiogenic potential of human Mesenchymal Stem/Stromal Cells in malignancy*. , 2019, , .		0
1143	Prospects of siRNA cocktails as tools for modifying multiple gene targets in the injured spinal cord. <i>Experimental Biology and Medicine</i> , 2019, 244, 1096-1110.	1.1	7
1144	MLL is required for miRNA-mediated translational repression. <i>Cell Discovery</i> , 2019, 5, 43.	3.1	3
1145	Machine Learning and Rule Mining Techniques in the Study of Gene Inactivation and RNA Interference. , 0, , .		2
1146	Efficient Knockdown and Lack of Passenger Strand Activity by Dicer-Independent shRNAs Expressed from Pol II-Driven MicroRNA Scaffolds. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 318-328.	2.3	13
1147	Adeno-associated virus vector as a platform for gene therapy delivery. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 358-378.	21.5	1,267
1148	Rapid Generation of Long Noncoding RNA Knockout Mice Using CRISPR/Cas9 Technology. <i>Non-coding RNA</i> , 2019, 5, 12.	1.3	12
1149	Biological Function and Application of Picornaviral 2B Protein: A New Target for Antiviral Drug Development. <i>Viruses</i> , 2019, 11, 510.	1.5	14
1150	Small RNAs to treat human immunodeficiency virus type 1 infection by gene therapy. <i>Current Opinion in Virology</i> , 2019, 38, 10-20.	2.6	11
1151	RNAi Therapy for Dominant Muscular Dystrophies and Other Myopathies. , 2019, , 491-507.		0
1152	Modeling the Kinetics of Lipid-Nanoparticle- Mediated Delivery of Multiple siRNAs to Evaluate the Effect on Competition for Ago2. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 367-377.	2.3	9
1153	Huntingtin Lowering Strategies for Disease Modification in Huntingtonâ€™s Disease. <i>Neuron</i> , 2019, 101, 801-819.	3.8	202
1154	MicroRNA in Lung Cancer Metastasis. <i>Cancers</i> , 2019, 11, 265.	1.7	55
1156	Rapid and Simple Screening of CRISPR Guide RNAs (gRNAs) in Cultured Cells Using Adeno-Associated Viral (AAV) Vectors. <i>Methods in Molecular Biology</i> , 2019, 1961, 111-126.	0.4	10
1157	Protein-based vehicles for biomimetic RNAi delivery. <i>Journal of Biological Engineering</i> , 2019, 13, 19.	2.0	9
1158	Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9. <i>Seminars in Liver Disease</i> , 2019, 39, 261-274.	1.8	21
1159	A systematic study on the influence of thermodynamic asymmetry of 5â€™-ends of siRNA duplexes in relation to their silencing potency. <i>Scientific Reports</i> , 2019, 9, 2477.	1.6	13

#	ARTICLE	IF	CITATIONS
1160	Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 202-222.	1.8	38
1161	Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 593-608.	2.3	44
1162	Small non-coding RNAs as a tool for personalized therapy in familial cancers. , 2019, , 179-208.		1
1163	RNA Interference Therapy for Machadoâ€“Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3. <i>Human Gene Therapy</i> , 2019, 30, 841-854.	1.4	18
1164	AhR Activation by TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin) Attenuates Pertussis Toxin-Induced Inflammatory Responses by Differential Regulation of Tregs and Th17 Cells Through Specific Targeting by microRNA. <i>Frontiers in Microbiology</i> , 2019, 10, 2349.	1.5	26
1165	A Sendai Virus-Based Cytoplasmic RNA Vector as a Novel Platform for Long-Term Expression of MicroRNAs. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 371-382.	1.8	7
1166	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	13.7	94
1167	siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model. <i>Journal of Drug Targeting</i> , 2019, 27, 325-337.	2.1	12
1168	Engineered zincâ€“finger nuclease to generate siteâ€“directed modification in the KLF1 gene for fetal hemoglobin induction. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8438-8446.	1.2	6
1169	Enhancement of gene knockdown efficiency by CNNC motifs in the intronic shRNA precursor. <i>Genes and Genomics</i> , 2019, 41, 491-498.	0.5	0
1170	Long-term RNAi knockdown of Î±-synuclein in the adult rat substantia nigra without neurodegeneration. <i>Neurobiology of Disease</i> , 2019, 125, 146-153.	2.1	38
1171	Insight into miRNAs related with glucometabolic disorder. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 657-665.	2.5	27
1172	Therapeutic Oligonucleotides: State of the Art. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 605-630.	4.2	208
1173	A simplified system for the effective expression and delivery of functional mature microRNAs in mammalian cells. <i>Cancer Gene Therapy</i> , 2020, 27, 424-437.	2.2	42
1174	Modulation of animal health through reverse genetics applications. , 2020, , 163-182.		2
1175	RNA interference therapeutics in organ transplantation: The dawn of a new era. <i>American Journal of Transplantation</i> , 2020, 20, 931-941.	2.6	45
1176	Dissimilar Appearances Are Deceptiveâ€“Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. <i>Cells</i> , 2020, 9, 114.	1.8	14
1177	Endogenous MicroRNA Competition as a Mechanism of shRNA-Induced Cardiotoxicity. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 572-580.	2.3	4

#	ARTICLE	IF	CITATIONS
1178	Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 562-571.	2.3	18
1179	Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells. <i>Materials Science and Engineering C</i> , 2020, 109, 110555.	3.8	52
1180	Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold. <i>Molecular Therapy</i> , 2020, 28, 422-430.	3.7	20
1181	A High-Content Screen Identifies MicroRNAs That Regulate Liver Repopulation After Injury in Mice. <i>Gastroenterology</i> , 2020, 158, 1044-1057.e17.	0.6	8
1182	In Vivo Cancer-Based Functional Genomics. <i>Trends in Cancer</i> , 2020, 6, 1002-1017.	3.8	5
1183	Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10267-10269.	1.6	7
1184	psRNAit: A Web Server for Designing Effective and Specific Plant siRNAs with Genome-Wide Off-Target Assessment. <i>Plant Physiology</i> , 2020, 184, 65-81.	2.3	54
1185	Multi-targeted gene silencing strategies inhibit replication of Canine morbillivirus. <i>BMC Veterinary Research</i> , 2020, 16, 448.	0.7	2
1186	An endoribonuclease-based feedforward controller for decoupling resource-limited genetic modules in mammalian cells. <i>Nature Communications</i> , 2020, 11, 5690.	5.8	65
1187	Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. <i>Viruses</i> , 2020, 12, 851.	1.5	49
1188	Dynamic global analysis of transcription reveals the role of miRNAs in synergistic stabilization of gene expression. <i>Science Bulletin</i> , 2020, 65, 2130-2140.	4.3	3
1189	Advances in oligonucleotide drug delivery. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 673-694.	21.5	1,036
1190	Germline engineering of the chicken genome using CRISPR/Cas9 by <i>in vivo</i> transfection of PGCs. <i>Animal Biotechnology</i> , 2023, 34, 775-784.	0.7	15
1191	RNA interference in glial cells for nerve injury treatment. <i>Journal of Tissue Engineering</i> , 2020, 11, 204173142093922.	2.3	8
1192	Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2020, 16, 529-546.	4.9	248
1193	SOD1-targeting therapies for neurodegenerative diseases: a review of current findings and future potential. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 379-392.	0.5	2
1194	Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5' UTR of SARS-CoV-2. <i>Epigenomics</i> , 2020, 12, 1349-1361.	1.0	34
1195	Viral Vectors Applied for RNAi-Based Antiviral Therapy. <i>Viruses</i> , 2020, 12, 924.	1.5	22

#	ARTICLE	IF	CITATIONS
1196	Short Hairpin RNAs for Strand-Specific Small Interfering RNA Production. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 940.	2.0	19
1197	Identification and comparison of the porcine H1, U6, and 7SK RNA polymerase III promoters for short hairpin RNA expression. <i>Mammalian Genome</i> , 2020, 31, 110-116.	1.0	0
1198	Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β^2 -hemoglobinopathies. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 84, 102456.	0.6	2
1199	Mouse models of tight junction physiology. , 2020, , 303-340.		0
1200	Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4197.	1.8	54
1201	Runx2 silencing promotes adipogenesis via downâ€­regulation of DLK1 in chondrogenic differentiating MSCs. <i>Journal of Gene Medicine</i> , 2020, 22, e3244.	1.4	4
1202	Discovering and validating cancer genetic dependencies: approaches and pitfalls. <i>Nature Reviews Genetics</i> , 2020, 21, 671-682.	7.7	41
1203	Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 1309-1329.	2.3	9
1204	ETMR: a tumor entity in its infancy. <i>Acta Neuropathologica</i> , 2020, 140, 249-266.	3.9	47
1205	MicroRNA-19a-PTEN Axis Is Involved in the Developmental Decline of Axon Regenerative Capacity in Retinal Ganglion Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 251-263.	2.3	20
1206	RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. <i>Cells</i> , 2020, 9, 137.	1.8	246
1207	RNA-based therapeutics in cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2020, 35, 191-198.	0.8	10
1208	XPO5 promotes primary miRNA processing independently of RanGTP. <i>Nature Communications</i> , 2020, 11, 1845.	5.8	21
1209	Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines. , 2020, , 351-369.		1
1210	Non-coding RNA therapeutics for cardiac regeneration. <i>Cardiovascular Research</i> , 2021, 117, 674-693.	1.8	56
1211	Recent Advances in miRNA Delivery Systems. <i>Methods and Protocols</i> , 2021, 4, 10.	0.9	136
1212	Oocyte-specific gene knockdown by intronic artificial microRNAs driven by <i>Zp3</i> transcription in mice. <i>Journal of Reproduction and Development</i> , 2021, 67, 229-234.	0.5	5
1213	In Vitro Silencing of lncRNA Expression Using siRNAs. <i>Methods in Molecular Biology</i> , 2021, 2348, 141-156.	0.4	3

#	ARTICLE	IF	CITATIONS
1214	Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry. <i>Theranostics</i> , 2021, 11, 8771-8796.	4.6	50
1215	Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart. <i>Pflügers Archiv European Journal of Physiology</i> , 2021, 473, 533-546.	1.3	5
1216	The Risks of miRNA Therapeutics: In a Drug Target Perspective. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 721-733.	2.0	116
1217	Correction of β^0 -thalassemia by CRISPR/Cas9 editing of the β -globin locus in human hematopoietic stem cells. <i>Blood Advances</i> , 2021, 5, 1137-1153.	2.5	41
1218	Oligonucleotide-Based Therapies for Renal Diseases. <i>Biomedicines</i> , 2021, 9, 303.	1.4	10
1219	Efficacy, accumulation, and transcriptional profile of anti-HIV shRNAs expressed from human U6, 7SK, and H1 promoters. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 1020-1034.	2.3	10
1220	Optimized Protocol for Accurate Titration of Adeno-Associated Virus Vectors. <i>Human Gene Therapy</i> , 2021, 32, 1270-1279.	1.4	11
1221	Current Therapeutic Approaches in FSHD. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 441-451.	1.1	18
1222	Context-aware synthetic biology by controller design: Engineering the mammalian cell. <i>Cell Systems</i> , 2021, 12, 561-592.	2.9	37
1223	Monocyte and Macrophage miRNA: Potent Biomarker and Target for Host-Directed Therapy for Tuberculosis. <i>Frontiers in Immunology</i> , 2021, 12, 667206.	2.2	20
1224	Noncoding RNA therapeutics – challenges and potential solutions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 629-651.	21.5	749
1225	Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	6
1226	Nanoliposomal Delivery of MicroRNA-203 Suppresses Migration of Triple-Negative Breast Cancer through Distinct Target Suppression. <i>Non-coding RNA</i> , 2021, 7, 45.	1.3	7
1227	Cationic oligonucleotide derivatives and conjugates: A favorable approach for enhanced DNA and RNA targeting oligonucleotides. <i>Beilstein Journal of Organic Chemistry</i> , 2021, 17, 1828-1848.	1.3	5
1228	In vivo Pooled Screening: A Scalable Tool to Study the Complexity of Aging and Age-Related Disease. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	1
1229	Synthetic gene circuits as tools for drug discovery. <i>Trends in Biotechnology</i> , 2022, 40, 210-225.	4.9	10
1230	Nanoparticle mediated <sc>RNA</sc> delivery for wound healing. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1741.	3.3	16
1231	Iminodibenzyl redirected cyclooxygenase-2 catalyzed dihomog γ -linolenic acid peroxidation pattern in lung cancer. <i>Free Radical Biology and Medicine</i> , 2021, 172, 167-180.	1.3	4

#	ARTICLE	IF	CITATIONS
1232	New Avenues for the Treatment of Huntington's Disease. International Journal of Molecular Sciences, 2021, 22, 8363.	1.8	55
1233	Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy. Neurotherapeutics, 2021, 18, 1524-1534.	2.1	16
1234	Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa. Nature Communications, 2021, 12, 4934.	5.8	18
1235	Intracellular controlled release prolongs the time period of siRNA-based gene suppression. Journal of Biomaterials Science, Polymer Edition, 2021, 32, 2088-2102.	1.9	1
1237	HOPX Exhibits Oncogenic Activity during Squamous Skin Carcinogenesis. Journal of Investigative Dermatology, 2021, 141, 2354-2368.	0.3	6
1238	In Vivo Inhibition of Marek's Disease Virus in Transgenic Chickens Expressing Cas9 and gRNA against ICP4. Microorganisms, 2021, 9, 164.	1.6	20
1239	Zn ²⁺ -Dependent peptide nucleic acid-based artificial ribonucleases with unprecedented efficiency and specificity. Chemical Communications, 2021, 57, 10911-10914.	2.2	7
1240	Pulmonary Delivery of Small Interfering RNA for Novel Therapeutics. , 0, , 269-289.		2
1241	In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector. Methods in Molecular Biology, 2020, 2115, 171-183.	0.4	4
1242	MiR-302-Mediated Somatic Cell Reprogramming and Method for Generating Tumor-Free iPS Cells Using miR-302. Methods in Molecular Biology, 2020, 2115, 199-219.	0.4	3
1243	RNAi Therapy for Dominant Muscular Dystrophies and Other Myopathies. , 2010, , 99-115.		6
1244	Hepatic Gene Therapy. Molecular Pathology Library, 2011, , 343-370.	0.1	1
1245	Lipidoids: A Combinatorial Approach to siRNA Delivery. Advances in Delivery Science and Technology, 2013, , 143-160.	0.4	4
1246	Cancer Cell Respiration: Hypoxia and pH in Solid Tumors. , 2013, , 183-206.		1
1247	Strategies for siRNA Navigation to Desired Cells. Methods in Molecular Biology, 2015, 1218, 201-216.	0.4	4
1248	Regulation of Receptor Tyrosine Kinases by miRNA: Overexpression of miRNA Using Lentiviral Inducible Expression Vectors. Methods in Molecular Biology, 2015, 1233, 135-147.	0.4	3
1249	Bioinformatics Tools for Achieving Better Gene Silencing in Plants. Methods in Molecular Biology, 2015, 1287, 43-60.	0.4	13
1250	Improved Models for Animal Research. , 2008, , 17-24.		3

#	ARTICLE	IF	CITATIONS
1251	Delivery of RNA Interference to Peripheral Neurons In Vivo Using Herpes Simplex Virus. <i>Methods in Molecular Biology</i> , 2010, 617, 347-361.	0.4	2
1252	Interference RNA for In vivo Knock-Down of Gene Expression or Genome-Wide Screening Using shRNA. <i>Methods in Molecular Biology</i> , 2010, 597, 189-209.	0.4	1
1253	Progress in the Therapeutic Applications of siRNAs Against HIV-1. <i>Methods in Molecular Biology</i> , 2009, 487, 1-26.	0.4	14
1254	Targeted Delivery of Antisense Oligonucleotides and siRNAs into Mammalian Cells. <i>Methods in Molecular Biology</i> , 2009, 487, 1-22.	0.4	7
1255	The Therapeutic Potential of LNA-modified siRNAs: Reduction of Off-target Effects by Chemical Modification of the siRNA Sequence. <i>Methods in Molecular Biology</i> , 2009, 487, 1-15.	0.4	49
1256	Engineering the Mouse Genome to Model Human Disease for Drug Discovery. <i>Methods in Molecular Biology</i> , 2010, 602, 55-77.	0.4	16
1257	Strategies in Designing Multigene Expression Units to Downregulate HIV-1. <i>Methods in Molecular Biology</i> , 2010, 623, 123-136.	0.4	11
1258	Current and Future Developments in Cancer Therapy Research: miRNAs as New Promising Targets or Tools. , 2012, , 517-546.		2
1259	Polymer-Based Delivery of RNA-Based Therapeutics in Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2013, 1049, 443-465.	0.4	3
1260	In Vivo Gene Silencing by Virally Delivered MicroRNA. <i>Neuromethods</i> , 2014, , 245-267.	0.2	1
1261	Helper-dependent adenoviral vectors. , 2010, , 193-207.		1
1262	MicroRNA Based Therapeutic Strategies for Cancer: Emphasis on Advances in Renal Cell Carcinoma. , 2014, , 175-188.		5
1263	miRNAs Targeting and Targeting miRNAs. , 2009, , 1-57.		1
1264	The Challenges and Current Advances in Delivering RNAi as Therapeutics. , 2013, , 189-224.		3
1265	Calcium Phosphate and Calcium Phosphosilicate Mediated Drug Delivery and Imaging. <i>Fundamental Biomedical Technologies</i> , 2011, , 713-744.	0.2	8
1266	Systematic Identification of Regulators of Oxidative Stress Reveals Non-canonical Roles for Peroxisomal Import and the Pentose Phosphate Pathway. <i>Cell Reports</i> , 2020, 30, 1417-1433.e7.	2.9	49
1268	Vector-Mediated and Viral Delivery of Short Hairpin RNAs. <i>RSC Biomolecular Sciences</i> , 2008, , 267-295.	0.4	3
1269	Development of an RNAi-Based Gene Therapy against HIV-1. <i>RSC Biomolecular Sciences</i> , 2008, , 296-315.	0.4	9

#	ARTICLE	IF	CITATIONS
1270	RNA Based Therapies for Treatment of HIV Infection. RSC Biomolecular Sciences, 2008, , 316-328.	0.4	2
1271	RNA interference of influenza A virus replication by microRNA-adapted lentiviral loop short hairpin RNA. Journal of General Virology, 2015, 96, 2971-2981.	1.3	12
1275	Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA. JCI Insight, 2019, 4, .	2.3	19
1276	Antisense oligonucleotide therapy for neurodegenerative disease. Journal of Clinical Investigation, 2006, 116, 2290-2296.	3.9	425
1277	Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?. Journal of Clinical Investigation, 2007, 117, 3633-3641.	3.9	132
1278	On futureâ€™s doorstep: RNA interference and the pharmacopeia of tomorrow. Journal of Clinical Investigation, 2007, 117, 3612-3614.	3.9	51
1279	Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. Journal of Clinical Investigation, 2010, 120, 3106-3119.	3.9	161
1280	Oligonucleotide therapeutic approaches for Huntington disease. Journal of Clinical Investigation, 2011, 121, 500-507.	3.9	121
1281	Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. Journal of Clinical Investigation, 2013, 123, 3876-3888.	3.9	170
1282	Recent Progress in Polymerase II-Mediated Intronic microRNA Expression Systems. , 2009, , 275-299.		2
1283	MicroRNA-Based RNA Polymerase II Expression Vectors for RNA Interference in Mammalian Cells. , 2009, , 301-315.		1
1284	Tailor-Made RNAs: From Self-Folding RNAs to Ribonucleoproteins. , 2014, , 251-262.		1
1285	Advances in systemic siRNA delivery. Drugs of the Future, 2009, 34, 721.	0.0	67
1286	Silencing Viral Infection. PLoS Medicine, 2006, 3, e242.	3.9	46
1287	SIRNA-Directed In Vivo Silencing of Androgen Receptor Inhibits the Growth of Castration-Resistant Prostate Carcinomas. PLoS ONE, 2007, 2, e1006.	1.1	52
1288	Silencing of Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Responsive Cancer Cells. PLoS ONE, 2008, 3, e2528.	1.1	29
1289	Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide. PLoS ONE, 2011, 6, e24308.	1.1	85
1290	Polymerase II Promoter Strength Determines Efficacy of microRNA Adapted shRNAs. PLoS ONE, 2011, 6, e26213.	1.1	31

#	ARTICLE	IF	CITATIONS
1291	XMRV Induces Cell Migration, Cytokine Expression and Tumor Angiogenesis: Are 22Rv1 Cells a Suitable Prostate Cancer Model?. PLoS ONE, 2012, 7, e42321.	1.1	11
1292	A Simple and Robust Vector-Based shRNA Expression System Used for RNA Interference. PLoS ONE, 2013, 8, e56110.	1.1	11
1293	MicroRNA-Mediated Myostatin Silencing in Caprine Fetal Fibroblasts. PLoS ONE, 2014, 9, e107071.	1.1	4
1294	shRNA Off-Target Effects In Vivo: Impaired Endogenous siRNA Expression and Spermatogenic Defects. PLoS ONE, 2015, 10, e0118549.	1.1	11
1295	The Highly Conserved Codon following the Slippery Sequence Supports a ⁺ 1 Frameshift Efficiency at the HIV-1 Frameshift Site. PLoS ONE, 2015, 10, e0122176.	1.1	14
1296	Novel AgoshRNA molecules for silencing of the CCR5 co-receptor for HIV-1 infection. PLoS ONE, 2017, 12, e0177935.	1.1	13
1297	Luciferase shRNA Presents off-Target Effects on Voltage-Gated Ion Channels in Mouse Hippocampal Pyramidal Neurons. ENeuro, 2017, 4, ENEURO.0186-17.2017.	0.9	10
1298	AAV8-mediated gene transfer of microRNA-132 improves beta cell function in mice fed a high-fat diet. Journal of Endocrinology, 2019, 240, 123-132.	1.2	12
1299	In Vivo Delivery Aspects of miRNA, shRNA and siRNA. Critical Reviews in Therapeutic Drug Carrier Systems, 2012, 29, 487-527.	1.2	56
1300	Role of MicroRNA in Mesenchymal Stem Cells Differentiation Into Osteoblasts. Razavi International Journal of Medicine, 2013, 1, 5-10.	0.1	3
1301	MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation. Oncoscience, 2014, 1, 830-843.	0.9	11
1302	Therapeutic Genes for Anti-HIV/AIDS Gene Therapy. Current Pharmaceutical Biotechnology, 2013, 14, 488-500.	0.9	6
1303	The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges. Current Topics in Medicinal Chemistry, 2019, 19, 2143-2157.	1.0	8
1304	MicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?. Current Neuropharmacology, 2017, 15, 260-275.	1.4	43
1306	Effects of the knockdown of hypoxia inducible factor-1 α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. The Korean Journal of Hepatology, 2010, 16, 280.	1.5	12
1307	RNA interference-based therapeutics for shrimp viral diseases. Diseases of Aquatic Organisms, 2009, 86, 263-272.	0.5	24
1308	Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World Journal of Gastroenterology, 2008, 14, 1670.	1.4	33
1309	RNA interference and antiviral therapy. World Journal of Gastroenterology, 2007, 13, 5169.	1.4	40

#	ARTICLE	IF	CITATIONS
1310	Helper-Dependent Adenoviral Vectors. <i>Journal of Genetic Syndromes & Gene Therapy</i> , 2011, 2, .	0.2	20
1311	Applications of RNA Interference in Schistosomiasis: Gene Function Identification and Development of New Therapies. <i>ISRN Parasitology</i> , 2013, 2013, 1-10.	0.6	17
1312	The role of microRNAs in synaptic development and function. <i>BMB Reports</i> , 2009, 42, 131-135.	1.1	36
1313	Microbial linguistics: perspectives and applications of microbial cell-to-cell communication. <i>BMB Reports</i> , 2011, 44, 1-10.	1.1	24
1314	Small RNA biology is systems biology. <i>BMB Reports</i> , 2011, 44, 11-21.	1.1	36
1315	Selection of RNAi-based inhibitors for anti-HIV gene therapy. <i>World Journal of Virology</i> , 2012, 1, 79.	1.3	16
1316	microRNAs as Therapeutic Targets to Combat Diverse Human Diseases. , 0, , .		1
1317	RNA Interference-Based Therapeutics: Harnessing the Powers of Nature. , 0, , .		2
1318	Application of Genome Editing Technology to MicroRNA Research in Mammalians. , 0, , .		2
1319	MicroRNA: from fundamental research to their application. <i>Biopolymers and Cell</i> , 2007, 23, 467-482.	0.1	2
1320	A novel animal model for neuroinflammation and white matter degeneration. <i>PeerJ</i> , 2017, 5, e3905.	0.9	4
1321	Evaluation of the Effects of Aluminum Phosphate and Calcium Phosphate Nanoparticles as Adjuvants in Vaccinated Mice. <i>International Journal of Chemical Engineering and Applications (IJCEA)</i> , 2014, 5, 367-373.	0.3	7
1322	RNA treatment kills mice. <i>Nature</i> , 0, , .	13.7	1
1324	<i>Gentherapie.</i> , 2008, , 379-394.		0
1325	Design of siRNAs and shRNAs for RNA Interference: Possible Clinical Applications. , 2008, , 109-130.		0
1326	Cardiac Delivery of Nucleic Acids by Transcriptional and Transductional Targeting of Adeno-Associated Viral Vectors. , 2008, , 167-181.		0
1327	Anti-HIV RNAs and Viral Vectors for Gene Therapy. <i>Journal of Life Science</i> , 2008, 18, 738-746.	0.2	0
1329	MicroRNAs in the Central Nervous System and Potential Roles of RNA Interference in Brain Tumors. , 2009, , 651-677.		1

#	ARTICLE	IF	CITATIONS
1330	siRNA/RNAi: Ein neuer Therapieansatz?. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2009, , 7-12.	0.0	0
1332	Lentiviral vector-mediated RNA interference of HBs gene inhibits replication of HBV. Academic Journal of Second Military Medical University, 2009, 29, 295-299.	0.0	0
1334	What Are the Key Targeted Delivery Technologies of siRNA Now?. Methods in Molecular Biology, 2010, 629, 91-105.	0.4	2
1335	A Look to the Future: Gene Therapy in Liver Diseases. , 2010, , 1403-1412.		0
1336	Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. Asian Journal of Andrology, 2011, 13, 181-182.	0.8	0
1337	RNA Interference and the Regulation of Renal Gene Expression in Hypoxia. , 2011, , 479-496.		0
1338	Delivery Strategies for RNAi to the Nervous System. Neuromethods, 2011, , 59-76.	0.2	0
1339	microRNA: A Potential Therapy Able to Target Multiple Cancer Pathways. , 2011, , 155-170.		0
1340	Using RNA Interference to Downregulate G Protein-Coupled Receptors. Neuromethods, 2011, , 379-402.	0.2	1
1341	Rapid Cloning and Validation of MicroRNA Shuttle Vectors: A Practical Guide. Neuromethods, 2011, , 19-37.	0.2	1
1342	Gene Therapy: Hopes and Problems. , 2011, , 7-17.		0
1343	Silencing the Disease Messengers. , 2011, , 85-111.		0
1344	Acute RNA Interference for Basic Research and Therapy. , 2011, , 1-16.		0
1345	Structural Diversity Repertoire of Gene Silencing Small Interfering RNAs. Oligonucleotides, 0, , 121102072334007.	2.7	0
1346	MicroRNAs as Biomarkers and Therapeutic Targets in Melanoma. , 2012, , 127-144.		0
1347	Targeting Neurological Disease with siRNA. Neuromethods, 2012, , 97-111.	0.2	0
1350	RNAi-Based Gene Expression Strategies to Combat HIV. , 0, , .		0
1351	NADPH Oxidase in Choroidal Neovascularization. , 2012, , 307-320.		0

#	ARTICLE	IF	CITATIONS
1352	Design of Synthetic shRNAs for Targeting Hepatitis C: A New Approach to Antiviral Therapeutics. , 2012, , 453-473.		0
1353	Neurodegeneration and Ageing: A Fatal Encounter. Cell & Developmental Biology, 2013, 02, .	0.3	2
1354	RNA Interference for Oncology: Clinical Prospects Beyond the Hype. , 2013, , 287-305.		0
1355	Nano-encapsulation of Oligonucleotides for Therapeutic Use. Nucleic Acids and Molecular Biology, 2014, , 245-260.	0.2	0
1356	Role of MicroRNA in Mesenchymal Stem Cells Differentiation Into Osteoblasts. Razavi International Journal of Medicine, 2013, 1, 5-10.	0.1	0
1358	MicroRNAs in the Development and Progression of Prostate Cancer. , 2014, , 265-286.		0
1359	RNA Interference as a Tool to Selectively Down-Modulate Protein Function. Neuromethods, 2014, , 177-194.	0.2	0
1360	Gene therapy using synthetic microRNA directed against GAD67 has beneficial effect on motor behaviour in 6-OHDA lesioned rats. Journal of Gene Therapy Aspects, 2014, 1, 1.	0.0	0
1361	Human diseases. , 2014, , 23-58.		0
1362	Epigenetik. , 2015, , 291-338.		0
1363	Adeno-Associated Virus and AAV Vectors for Gene Delivery. , 2015, , 85-132.		0
1365	Gene Therapy for Huntingtonâ€™s Disease. Neuromethods, 2015, , 121-151.	0.2	0
1367	Computational Systems Bioinformatics for RNAi. , 2016, , 646-651.		0
1369	Biomarker and Therapeutic Targets for Tuberculosis: A Role of Micro RNAs. Journal of Investigative Genomics, 2016, 3, .	0.2	1
1370	Chapter 12 Regulation of Calcium Uptake into the Sarcoplasmic Reticulum in the Heart. , 2016, , 303-332.		0
1373	Two faces of competition: targetâ€‘mediated reverse signalling in microRNA and mitogenâ€‘activated protein kinase regulatory networks. IET Systems Biology, 2017, 11, 105-113.	0.8	1
1374	Huntingtonâ€™s Disease and Other Polyglutamine Repeat Diseases. , 2018, , 145-188.		0
1375	Advances and Challenges of RNAi-Based Anti-HIV Therapeutics. RSC Drug Discovery Series, 2019, , 266-291.	0.2	0

#	ARTICLE	IF	CITATIONS
1376	RNA Interference Technology. , 2019, , 560-575.		18
1380	CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUPâ€B15 cells. Molecular Medicine Reports, 2020, 22, 2791-2800.	1.1	1
1381	An RNA Interference/Adenoâ€Associated Virus Vectorâ€Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus. Hepatology Communications, 2022, 6, 878-888.	2.0	12
1382	Generating DNA Expression Cassettes Encoding Multimeric Artificial MicroRNA Precursors. Methods in Molecular Biology, 2020, 2115, 185-197.	0.4	0
1383	Gene therapy for liver diseases: experimental strategies. , 0, , 139-153.		0
1384	siRNA Therapeutic Design: Tools and Challenges. , 2012, , 475-503.		0
1385	The Challenges and Current Advances in Delivering RNAi as Therapeutics. , 2013, , 189-224.		1
1386	A review of antisense therapeutic interventions for molecular biological targets in asthma. Biologics: Targets and Therapy, 2007, 1, 271-83.	3.0	17
1387	A novel expression system for artificial miRNAs containing no endogenous miRNA precursor sequences. Journal of Rnai and Gene Silencing, 2007, 3, 237-47.	1.2	3
1388	Native microRNA loop sequences can improve short hairpin RNA processing for virus gene silencing in animal cells. Journal of Rnai and Gene Silencing, 2008, 4, 295-301.	1.2	7
1393	Evaluation of RNA-knockdown strategies for modulation of cytochrome P450 reductase activity in mouse hepatocytes. Journal of Rnai and Gene Silencing, 2010, 6, 416-21.	1.2	1
1396	In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. Journal of Rnai and Gene Silencing, 2011, 7, 434-42.	1.2	25
1397	Optimizing siRNA delivery to the genital mucosa. Discovery Medicine, 2011, 11, 124-32.	0.5	6
1398	siRNA-based topical microbicides targeting sexually transmitted infections. Current Opinion in Molecular Therapeutics, 2010, 12, 192-202.	2.8	7
1400	Gene therapy in animal models of autosomal dominant retinitis pigmentosa. Molecular Vision, 2012, 18, 2479-96.	1.1	47
1401	Expression levels of microRNA machinery components Drosha, Dicer and DGCR8 in human (AGS, HepG2,) Tj ETQq1 1 0.784314 rgBT /Dx 269-74.	1.3	17
1403	Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors. Acta Naturae, 2013, 5, 7-18.	1.7	8
1404	Non-coding RNAs as therapeutic targets in hepatocellular cancer. Current Cancer Drug Targets, 2012, 12, 1073-80.	0.8	26

#	ARTICLE	IF	CITATIONS
1407	Effects of Pathogenic Variations in the Human Rhodopsin Gene (hRHO) on the Predicted Accessibility for a Lead Candidate Ribozyme. , 2017, 58, 3576-3591.		3
1408	An Antisense Transcript Transcribed From <i>Irs2</i> Locus Contributes to the Pathogenesis of Hepatic Steatosis in Insulin Resistance. SSRN Electronic Journal, 0, , .	0.4	0
1409	Delivery of pDNA to the Lung by Lipopolyplexes Using N-Lauroylsarcosine and Effect on the Pulmonary Fibrosis. Pharmaceutics, 2021, 13, 1983.	2.0	4
1410	Molecular Strategies to Target Protein Aggregation in Huntington's Disease. Frontiers in Molecular Biosciences, 2021, 8, 769184.	1.6	21
1411	In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses, 2021, 13, 2247.	1.5	1
1412	Efficient and Precise Processing of the Optimized Primary Artificial MicroRNA in a Huntingtin-Lowering Adeno-Associated Viral Gene Therapy <i>In Vitro</i> and in Mice and Nonhuman Primates. Human Gene Therapy, 2022, 33, 37-60.	1.4	4
1413	Implementation of RNAi-based arthropod pest control: environmental risks, potential for resistance and regulatory considerations. Journal of Pest Science, 2022, 95, 1-15.	1.9	22
1414	An antisense transcript transcribed from <i>Irs2</i> locus contributes to the pathogenesis of hepatic steatosis in insulin resistance. Cell Chemical Biology, 2022, , .	2.5	2
1415	RNAi-Based Biocontrol Products: Market Status, Regulatory Aspects, and Risk Assessment. Frontiers in Insect Science, 2022, 1, .	0.9	36
1416	Ex Vivo and In Vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors. Molecular Therapy, 2022, 30, 2005-2023.	3.7	10
1417	RPE based gene and cell therapy for inherited retinal diseases: A review. Experimental Eye Research, 2022, 217, 108961.	1.2	4
1418	Harnessing Intronic microRNA Structures to Improve Tolerance and Expression of shRNAs in Animal Cells. Methods and Protocols, 2022, 5, 18.	0.9	1
1419	CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa. Molecular Therapy, 2022, 30, 1407-1420.	3.7	16
1420	Insights into gene manipulation techniques for Acari functional genomics. Insect Biochemistry and Molecular Biology, 2022, 143, 103705.	1.2	3
1421	Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics. Journal of Experimental and Clinical Cancer Research, 2021, 40, 383.	3.5	22
1422	Innovative developments and emerging technologies in RNA therapeutics. RNA Biology, 2022, 19, 313-332.	1.5	19
1424	In Silico Prediction and Selection of Target Sequences in the SARS-CoV-2 RNA Genome for an Antiviral Attack. Viruses, 2022, 14, 385.	1.5	2
1425	Xenogenic Neural Stem Cell-Derived Extracellular Nanovesicles Modulate Human Mesenchymal Stem Cell Fate and Reconstruct Metabolomic Structure. Advanced Biology, 2022, 6, e2101317.	1.4	5

#	ARTICLE	IF	CITATIONS
1426	A versatile transposon-based technology to generate loss- and gain-of-function phenotypes in the mouse liver. <i>BMC Biology</i> , 2022, 20, 74.	1.7	1
1427	VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 58-76.	2.3	6
1428	Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. <i>Virology Journal</i> , 2021, 18, 247.	1.4	4
1429	Are We Studying Non-Coding RNAs Correctly? Lessons from nc886. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4251.	1.8	12
1430	Exosomal and Non-Exosomal MicroRNAs: New Kids on the Block for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4493.	1.8	9
1431	Molecular Signature of Astrocytes for Gene Delivery by the Synthetic Adeno-associated Viral Vector rAAV9P1. <i>Advanced Science</i> , 2022, 9, e2104979.	5.6	7
1432	Right on target: The next class of efficient, safe, and specific RNAi triggers. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 363-365.	2.3	2
1439	Unpacking extracellular vesicles: RNA cargo loading and function. , 2022, 1, .		28
1440	A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 702-715.	2.3	4
1441	The Short Hairpin RNA Driven by Polymerase II Suppresses both Wild-Type and Lamivudine-Resistant Hepatitis B Virus Strains. <i>Antiviral Therapy</i> , 2007, 12, 865-876.	0.6	4
1442	Current and Possible Future Therapeutic Options for Huntington's Disease. <i>Journal of Central Nervous System Disease</i> , 2022, 14, 117957352210925.	0.7	25
1443	F5HD Therapeutic Strategies: What Will It Take to Get to Clinic?. <i>Journal of Personalized Medicine</i> , 2022, 12, 865.	1.1	3
1444	Endogenous spacing enables co-processing of microRNAs and efficient combinatorial RNAi. <i>Cell Reports Methods</i> , 2022, , 100239.	1.4	3
1445	Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	9
1446	Emerging Approaches for Enabling RNAi Therapeutics. <i>Chemistry - an Asian Journal</i> , 0, , .	1.7	2
1447	Suppression of osteoclast multinucleation via a posttranscriptional regulation-based spatiotemporally selective delivery system. <i>Science Advances</i> , 2022, 8, .	4.7	17
1448	Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
1449	Limiting Transactivator Amounts Contribute to Transgene Mosaicism in Tet-On All-in-One Systems. <i>ACS Synthetic Biology</i> , 2022, 11, 2623-2635.	1.9	5

#	ARTICLE	IF	CITATIONS
1450	RNA-based therapeutics: an overview and prospectus. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	137
1451	RISC-y Business: Limitations of Short Hairpin RNA-Mediated Gene Silencing in the Brain and a Discussion of CRISPR/Cas-Based Alternatives. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	10
1452	siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy. <i>OpenNano</i> , 2022, 7, 100063.	1.8	13
1453	Phosphoproteomics of three exercise modalities identifies canonical signaling and C18ORF25 as an AMPK substrate regulating skeletal muscle function. <i>Cell Metabolism</i> , 2022, 34, 1561-1577.e9.	7.2	26
1454	AAV2/9-mediated gene transfer into murine lacrimal gland leads to a long-term targeted tear film modification. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 1-16.	1.8	0
1455	The discovery and development of RNA-based therapies for treatment of HIV-1 infection. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 163-179.	2.5	5
1456	Harnessing nucleic acid technologies for human health on earth and in space. <i>Life Sciences in Space Research</i> , 2022, 35, 113-126.	1.2	2
1458	Transposition of polymer-encapsulated small interfering RNA through lung surfactant models at the air-water interface. <i>Chemical Physics</i> , 2022, 563, 111704.	0.9	1
1459	Polymeric micelles for drug delivery in oncology with an emphasis on siRNA conveyance. , 2022, , 199-284.		0
1460	Polypharmacology in Drug Design and Discoveryâ€™Basis for Rational Design of Multitarget Drugs. , 2022, , 397-533.		1
1461	Modifying organs with gene therapy and gene modulation in the age of machine perfusion. <i>Current Opinion in Organ Transplantation</i> , 2022, 27, 474-480.	0.8	3
1462	Hepatitis B Virus Research in South Africa. <i>Viruses</i> , 2022, 14, 1939.	1.5	7
1463	WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects. <i>Molecular Therapy</i> , 2023, 31, 435-453.	3.7	10
1465	Specificity of oligonucleotide gene therapy (OGT) agents. <i>Theranostics</i> , 2022, 12, 7132-7157.	4.6	14
1466	Characteristics of environmental RNAi in potato psyllid, <i>Bactericera cockerelli</i> (Sulc) (Hemiptera:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	1.3	5
1467	Chicken genome editing for investigating poultry pathogens. <i>Avian Pathology</i> , 2023, 52, 1-11.	0.8	2
1468	Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. <i>Nature Communications</i> , 2022, 13, .	5.8	13
1469	RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases. <i>Molecular Aspects of Medicine</i> , 2023, 91, 101148.	2.7	5

#	ARTICLE	IF	CITATIONS
1470	Effects of Houpo Mahuang Decoction on serum metabolism and TRPV1/Ca2+/TJs in asthma. <i>Journal of Ethnopharmacology</i> , 2023, 302, 115873.	2.0	2
1471	How global RNA-binding proteins coordinate the behaviour of RNA regulons: An information approach. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 6317-6338.	1.9	1
1472	Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13929.	1.8	3
1474	Proteome-wide systems genetics identifies UFMylation as a regulator of skeletal muscle function. <i>ELife</i> , 0, 11, .	2.8	7
1475	Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	7
1476	Small RNAs/ <i>Cancer</i> . , 2016, , 727-738.		0
1477	RNA Interference Applications for Machado-Joseph Disease. , 0, , .		0
1478	Burgeoning therapeutic strategies to curb the contemporary surging viral infections. <i>Microbial Pathogenesis</i> , 2023, 179, 106088.	1.3	0
1479	Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. <i>Nature Communications</i> , 2023, 14, .	5.8	14
1480	The future of sickle cell disease therapeutics rests in genomics. <i>DMM Disease Models and Mechanisms</i> , 2023, 16, .	1.2	9
1481	Chemistry, structure and function of approved oligonucleotide therapeutics. <i>Nucleic Acids Research</i> , 2023, 51, 2529-2573.	6.5	110
1482	Rhodopsin-associated retinal dystrophy: Disease mechanisms and therapeutic strategies. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	3
1483	DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors. <i>Cancers</i> , 2023, 15, 2151.	1.7	4
1484	Proof-of-concept study for liver-directed miQURE technology in a dyslipidemic mouse model. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 32, 454-467.	2.3	0
1485	A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor. <i>Nature Biomedical Engineering</i> , 2023, 7, 1063-1080.	11.6	3
1486	Development of RNAi-based biopesticides, regulatory constraints, and commercial prospects. , 2023, , 149-171.		0
1487	<i>Nucleic Acid Therapeutics</i> . , 2022, , 350-402.		0
1490	Therapeutic targeting non-coding RNAs. , 2023, , 349-417.		0

#	ARTICLE	IF	CITATIONS
1509	Intrathecal Delivery of Viral Vector-Mediated Gene Therapy. , 2023, , 399-412.		0
1510	Molecular prospects of transcription activator-like effector nucleases (TALENs) in cancer management: Challenges and adaptations. , 2024, , 275-283.		0
1511	RNA therapeutics for diarrhea. Progress in Molecular Biology and Translational Science, 2024, , 295-309.	0.9	0
1513	Huntingtin lowering therapeutics. , 2024, , 523-549.		0